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“If your mouth is open, you are not learning” – Buddha 
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ABSTRACT 
Defects of mitochondrial DNA (mtDNA) replication underlie common 
metabolic disorders. Despite mtDNA is degraded and synthesised in all cells 
containing mitochondria, mtDNA replication stress typically causes 
generation of mtDNA deletions or depletion of mtDNA copy number in muscle 
and brain, which manifest as mitochondrial myopathy (MM) or 
neurodegeneration, respectively. MtDNA replication defects, however, do not 
affect highly proliferative tissues, such as blood or intestine, despite their 
reliance on robust mtDNA replication to sustain high rates of proliferation. 
The mechanisms behind the tissue-specific manifestations of mtDNA 
replication defects remain unknown. 
In this thesis, we aimed to identify the metabolic response pathways for 
mtDNA replication stress caused by a dominant Twinkle mtDNA helicase 
(TWNK) mutation leading to adult-onset MM. We collected samples from MM 
patients and a MM mouse model, Deletor mouse, for a multi-tissue metabolic 
characterisation. The study revealed that MM induces a metabolic 
reprogramming in the muscle directing glucose consumption to serine 
synthesis to support cysteine production by transsulfuration pathway. The 
metabolic response also remodels vitamin B9 (folate) metabolism and causes 
imbalance in whole-cellular deoxynucleotide triphosphate (dNTP) pools, 
which are likely novel contributors in the progressive mtDNA mutagenesis. 
The characterised metabolic stress response for the mtDNA replication defect 
was found to be orchestrated by one master regulator, mechanistic target of 
rapamycin complex I (mTORC1). The mTORC1-mediated stress response 
appeared to promote disease progression, and an mTORC1 inhibitor, 
rapamycin, remarkably improved the mitochondrial muscle disease. It 
ameliorated the typical hallmarks of MM: the number of ragged red fibers 
(RRFs) and the amount of mtDNA deletions were reduced after rapamycin 
treatment. 
In the second part of this thesis, we studied the transcription regulation of 
mtDNA replication machinery. We identified a complex regulatory locus for 
DNA polymerase gamma (POLG) by in silico predictions, which were verified 
in vivo. The regulatory non-coding locus drives POLG expression specifically 
in the sensory interneurons of the spinal cord and oculomotor nucleus, which 
we found to degenerate in POLG patients. The death of these neurons might 
be the underlying cause of sensory neuropathy and progressive external 
ophthalmoplegia (PEO), which are typical clinical findings in POLG disorders. 
The identified regulatory locus functions through a non-coding RNA and three 
enhancer elements but also contains MIR-9, which targets the mitochondrial 
folate pathway by downregulating methylene tetrahydrofolate dehydrogenase 
2 (MTHFD2). Therefore, this locus provides an unexpected link between the 
expression of POLG and mitochondrial folate metabolism. 
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In conclusion, our work has identified novel contributors in the tissue-
specific manifestations of mitochondrial diseases and offers multiple novel 
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Cellular metabolism is compartmentalised: major metabolic pathways 
function in organelles that are separated from the cytoplasm by lipid 
membranes. The isolated nature of cellular organelles enables them to execute 
processes that require specialised environment. For example, low pH is 
essential for the function of lysosomal enzymes, whereas highly regulated 
redox environment is required for mitochondrial oxidative phosphorylation 
(Hu et al., 2008). Mitochondria also perform a variety of other essential 
metabolic functions and are, therefore, critical for cellular metabolism. Some 
pathways function solely within the mitochondrial compartment (e.g. the 
tricarboxylic acid (TCA) cycle), but others function partly in cytoplasm and 
partly in mitochondria (e.g. the folate cycle). Cellular metabolism is, therefore, 
highly dependent on the efficient cross-talk of the cytoplasmic and 
mitochondrial compartments, but the signalling between these compartments 
is currently poorly characterised. Also, the cytoplasmic responses to 
mitochondrial dysfunction remain largely unknown. 
MtDNA replication defects are a major cause of mitochondrial disorders. 
Mutations in mtDNA replication enzymes cause the loss of mtDNA integrity 
and induce mtDNA depletion or accumulation of mtDNA deletions, which 
underlie various human disorders. The loss of mtDNA integrity has 
detrimental consequences on cellular metabolism beyond the respiratory 
chain function and adenosine triphosphate (ATP) production since it has also 
been linked to mitochondrial translation defects, which induce mitochondrial 
membrane stress. Functional mitochondrial translation is critical in 
maintaining mitochondrial membrane potential, which is required for 
efficient mitochondrial membrane trafficking. 
Mitochondrial diseases belong to the group of metabolic disorders, but the 
exact biochemical consequences of mtDNA replication defects to metabolic 
pathways are not well known. Identifying the molecular consequences of 
mitochondrial dysfunction to cellular metabolism has a critical role in 
designing effective interventions and developing new treatments. Currently no 
cure can be offered to patients suffering from mitochondrial diseases, but the 
available treatments only alleviate disease symptoms and provide palliative 
care.  
In this thesis, we describe the metabolic consequences of mtDNA 
replication defects in vivo. 
Review of the literature 
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2 REVIEW OF THE LITERATURE 
2.1 THE STRUCTURE AND FUNCTIONS OF 
MITOCHONDRIA 
2.1.1 THE ORIGIN OF MITOCHONDRIA 
Mitochondria are intracellular organelles of eukaryotic cells. They form a 
dynamic network, which undergoes constant fission and fusion events (Figure 
1). Mitochondria are thought to originate from an endosymbiotic event where 
an ancestral prokaryote, α-proteobacterium, was engulfed by another cell 
(Margulis, 1970). The current structure of mitochondria resembles the 
ancestral prokaryote as both have a double-membrane structure, circular 
genome and their own transcription and translation systems. Prokaryotes and 
mitochondria both transcribe a long polycistronic RNA product and use N-
formylmethionine (fMet) in translation initiation (Gray, 2012). Also, some 
mitochondrial proteins, such as 60- and 70 kDa heat shock proteins (HSP60, 
HSP70), have α-proteobacterium homologues, but they are currently encoded 
by the ancestral host genome, translated in the cytoplasmic ribosomes and 
imported to mitochondria, where they originally functioned. This 
phenomenon is called endosymbiotic gene transfer, and it happened during 
the reduction of mtDNA molecule. (Timmis et al., 2004) 
 
  
Figure 1 (A) Human myoblast showing mitochondrial network in red (Mitotracker) and DNA in 
blue (DAPI). Scale bar: 10 µm. (B) Magnification of mitochondria from (A). Scale 
bar: 10 µm (C) Electron micrograph of a mitochondrion from human fibroblast. 
Scale bar: 200 nm. Imaging by Christopher Jackson. 
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Whereas α-proteobacterium is generally accepted to be the ancestor of 
mitochondria, different theories exist for the nature of the host and the 
beneficial function of the cytoplasmic parasite for the host cell. The most 
common view states that the host cell was an anaerobic eukaryote, which 
engulfed the mitochondrion by active phagocytosis. The initial benefit of the 
mitochondrial endosymbiont for the host cell might have been its ability to 
consume and, thereby, detoxify oxygen from the environment. This theory 
assumes that all initial eukaryotes, except the ones with mitochondria, went 
extinct as no eukaryotic cells without mitochondria exist. Another theory 
suggests that the original host cell was an archaea that benefited from the 
endosymbiont’s ability to produce H2, which the host utilised as a source of 
energy and electrons (Embley and Martin, 2006). 
2.1.2 THE FUNCTIONS OF MITOCHONDRIA 
Mitochondria perform various anabolic and catabolic activities. Most 
mitochondrial functions, however, do not have an essential role for eukaryotic 
life. For example, the complete loss of mtDNA molecule, which encodes 
essential subunits for cellular respiration, does not show detrimental 
consequences in yeast Saccharomyces cerevisiae, which is able to grow 
without mtDNA in the presence of a fermentable carbon source (Williamson, 
2002). 
The most conserved essential mitochondrial function, present in all 
eukaryotes, is the synthesis of iron-sulphur clusters, which happens in the 
mitochondrial matrix (Lill and Kispal, 2000). Mutant yeast strains incapable 
of synthesising iron-sulphur clusters fail to grow under any conditions due to 
the lack of functional extra-mitochondrial iron-sulphur cluster proteins 
(Kispal et al., 2005; Lill et al., 1999). However, most mitochondrial functions, 
such as beta-oxidation and the function of the respiratory chain, are essential 
for higher organisms, such as humans, and defects in those pathways underlie 
a broad spectrum of human diseases (Gerards et al., 2016; Wanders et al., 
1989). 
2.1.2.1 Respiratory chain and oxidative phosphorylation 
The best-known role of mitochondria is to provide ATP molecules through 
oxidative phosphorylation (OXPHOS) (Mitchell, 1961). This is catalysed by 
five large enzyme complexes, which reside in the folded inner membrane of 
the mitochondria (Figure 2). The respiratory chain consists of complexes I-IV 
that pump protons to create an electrochemical gradient across the inner 
mitochondrial membrane, which is utilised by complex V to convert adenosine 
diphosphate (ADP) to ATP (Boyer et al., 1973). Most of the subunits of the five 
complexes are encoded in the nucleus and imported into mitochondria, but 13 
of the hydrophobic core subunits of complexes I, III, IV and V are encoded by 
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mtDNA and translated by mitochondrial ribosomes. The successful assembly 
of the complexes requires an exceptional coordination of mitochondrial 
protein import, expression of the mitochondrial genome and insertion of the 
subunits into the inner membrane. 
Figure 2 Schematic picture of oxidative phosphorylation. Electron carriers ubiquinone (blue 
ball) and cytochrome c (purple ball) shuttle electrons to respiratory chain 
complexes. The complexes pump protons to the intermembrane space to create an 
electrochemical gradient across the inner mitochondrial membrane. This gradient is 
utilised by complex V to convert ADP and Pi to ATP.  
Complex I, or NADH dehydrogenase, consists of 45 protein subunits, 7 of 
which are mitochondrial encoded. This complex is one of the two entry points 
of the respiratory chain as it obtains two electrons by oxidising two NADH 
molecules that derive from the TCA cycle. The electrons are shuttled through 
iron-sulphur clusters to a lipid-soluble carrier, ubiquinone, which is converted 
to its reduced form, ubiquinol (Baradaran et al., 2013). During this process 
four protons are pumped to the intermembrane space. Importantly, in 
addition to the reduction of ubiquinone and proton pumping, the role of 
complex I in NADH oxidation is critical in providing sufficient NAD+ flux to 
the TCA cycle (Martinez-Reyes et al., 2016). An additional link between the 
TCA cycle and the respiratory chain is complex II, succinate dehydrogenase, 
which is the only complex that is part of both of these pathways. Complex II is 
the second entry point to the respiratory chain, but instead of NADH, it uses 
flavin adenine dinucleotide (FADH2) in the reaction that does not involve 
proton pumping but reduces one molecule of ubiquinone and converts 
succinate to fumarate. 
The ubiquinol molecules provided by complexes I and II diffuse within the 
inner mitochondrial membrane and are used by complex III, coenzyme 
Q:cytochrome c oxidoreductase. This complex, as its name suggests, uses 
ubiquinol to reduce two molecules of cytochrome c, which is the other electron 
carrier in the respiratory chain. As a result of this reaction, complex III pumps 
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two protons to the intermembrane space. The reduced cytochrome c is utilised 
by complex IV, cytochrome c oxidase, which is the last enzyme complex of the 
respiratory chain. It transfers the electrons from cytochrome c to O2 producing 
H2O, and protons are pumped across the membrane during this process. 
(Saraste, 1999) 
The energy stored in the electrochemical gradient, created by the 
respiratory chain, is utilised by complex V, ATP synthase, which converts ADP 
and Pi into ATP (Mitchell, 1961). ATP synthase consists of a water-soluble F1 
part and a F0 ring-like structure, which is located in the membrane (Abrahams 
et al., 1994). These two parts are connected by the central and peripheral 
stalks. When the protons flow through the F0 ring structure, the membrane-
bound F0-part and the central stalk rotate, but F1-part is prevented from 
rotating by the peripheral stalk. The rotation of the central stalk within the F1-
part activates the reaction of the ATP synthesis (Abrahams et al., 1994; Gresser 
et al., 1982; Stock et al., 2000). 
The OXPHOS complexes form so called supercomplexes where multiple 
complexes are physically and functionally linked (Schagger and Pfeiffer, 
2000). They are found in multiple respiratory chain complex combinations: 
(I+III), (I+III+IV) and (III+IV), but complex II has not been found to 
associate with these supercomplexes (Dudkina et al., 2005; Heinemeyer et al., 
2007; Schagger and Pfeiffer, 2000). Supercomplexes are characterised from 
multiple species and are detected by blue-native polyacrylamide gel 
electrophoresis and electron microscopy single-particle analysis (Chaban et 
al., 2014; Minauro-Sanmiguel et al., 2005). Also, ATP synthase is found as a 
dimeric complex in yeast, Arabidopsis, Bos taurus and several other species 
(Arnold et al., 1998; Eubel et al., 2003). The dimerisation of ATP synthase has 
been associated to crista formation and to maintenance of the folded nature of 
the mitochondrial inner membrane (Dudkina et al., 2010; Strauss et al., 
2008). This is supported by studies in yeast, where disintegration of the ATP 
synthase dimer disrupts the mitochondrial ultrastructure leading to onion-like 
and balloon-shaped mitochondria (Davies et al., 2012). 
2.1.2.2 One-carbon metabolism 
One-carbon (1C) metabolism is a metabolic pathway, which is essential to 
virtually all cell types and all organisms. It provides 1C-units to major anabolic 
cellular pathways: nucleotide synthesis, methylation reactions and 
mitochondrial translation initiation (Figure 3) (Tong et al., 2009). The carrier 
of activated 1C-units is folate (vitamin B9), which functions in its reduced 
form, tetrahydrofolate (THF), and accepts 1C-units from 1C-donors, mainly 
serine and glycine (Shane and Stokstad, 1985). THF can function in several 
different oxidative states, enabling it to serve as an enzyme cofactor in 
different reactions. The conversion of different THF intermediates forms a 
cyclic pathway, which has cytoplasmic and mitochondrial parts. The 
mitochondrial compartment is thought to have its own stable THF 
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intermediate pool, maintained by active transport of THF into mitochondria 
by the function of SLC25A32. No exchange of activated THF forms between 
the two compartments have been reported. (Cook and Blair, 1979; Titus and 
Moran, 2000; Zamierowski and Wagner, 1977) 
Mitochondrial folate metabolism uses THF and 1C-donors serine, glycine 
or sarcosine as inputs and produces fMet for mitochondrial translation 
initiation, NADPH and formate (Fan et al., 2014). Formate can pass through 
mitochondrial membrane without active transport, and it is suggested to be 
the major 1C-source for cytoplasmic 10-formyl-THF used for inosine 
monophosphate production, which is the end product of de novo purine 
synthesis. 10-formyl-THF is used by GAR transformylase and AICAR 
transformylase, which catalyse two steps in the pathway. Compromised 10-
formyl-THF production affects first AICAR transformylase given its lower Km 
for 10-formyl-THF compared to GAR transformylase (Mueller and Benkovic, 
1981; Smith et al., 1981). Suboptimal function of AICAR transformylase leads 
to accumulation of its substrate, AICAR, which is a direct activator of AMP-
activated protein kinase (AMPK) (Herbert et al., 1964; Li et al., 2016). AMPK 
plays a critical role in cellular energy homeostasis and when activated, blocks 
cellular anabolism (Hardie et al., 2012). The availability of 10-formyl-THF, 
thereby, links nutrient (folate) availability and mitochondrial folate 
metabolism to AMPK-mediated nutrient sensing. 
To date, NADPH production by folate cycle has only been observed in 
cultured cells and its in vivo significance remains unclear. In vitro data 
indicate that NADPH from the folate cycle is critical in reduction of oxidised 
glutathione and, thereby, important for reactive oxygen species (ROS) 




Figure 3 Schematic picture of 1C-metabolism and folate intermediates. End-products shown 
in bold.  
In addition to purine synthesis, cytoplasmic folate pathway is critical for 
maintaining the function of the methyl cycle, which provides s-adenosyl-
methionine (SAM) (Figure 4). SAM is the sole methyl donor in the cell and, 
therefore, the substrate for all methyltransferases, which catalyse the 
methylation of DNA, RNA, proteins and metabolites (Anderson et al., 2012; 
Zatz et al., 1981). The synthesis of SAM is dependent on the conversion of 
homocysteine to methionine. This is catalysed by methionine synthase, which 
uses 5-methyl-THF as a cofactor (Stipanuk, 2004). When the intake of dietary 
folate is compromised and intracellular folate intermediate pools are reduced, 
homocysteine accumulates as one of the first signs of folate deficiency 
(Collaboration, 1998). Increased level of homocysteine has been associated to 
several human conditions, e.g.  cardiovascular diseases, highlighting the 
importance of sufficient folate intake. In addition, accumulation of 
homocysteine can also bind to s-adenosyl-homocysteine hydrolase (SAHH), 
which functions as the scavenger of the side product of methylation reactions, 
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s-adenosyl-homocysteine (SAH) (Palmer and Abeles, 1979). The binding of 
homocysteine to SAHH inhibits its activity resulting in accumulation of 
intracellular SAH, which is a potent inhibitor of methyltransferases and, 
thereby, disturbs different methylation reactions in the cell (Hoffman et al., 
1980; James et al., 2002). 
Figure 4 Schematic picture of methyl cycle. Abbreviations: SAM, S-adenosyl-methionine; 
SAH, S-adenosyl-homocysteine; THF, tetrahydrofolate 
2.1.3 MITOCHONDRIAL DNA AND ITS REPLICATION 
Mitochondria harbour their own genome, which is 16 569 base pairs (bp) long 
and encodes 13 polypeptides, 22 transfer RNAs (tRNAs) and 2 ribosomal 
RNAs (rRNAs) (Anderson et al., 1981). The products of all genes encoded by 
mtDNA are used within the organelle: protein-coding genes encode subunits 
of OXPHOS and the functional RNAs are required for mitochondrial 
translation (Figure 5). The vast majority of the mitochondrial proteome 
(~1200 proteins in total) is encoded by the nuclear DNA, translated in 
cytoplasmic ribosomes and imported into mitochondria (Calvo et al., 2016). 
The imported proteins have their specified functions and are responsible e.g. 
for the replication of mtDNA, which takes place in all tissues, including post-
mitotic tissues in which nuclear DNA is not replicating. The number of mtDNA 
molecules per cell varies from hundreds to thousands of copies depending on 
the cell type. This creates, together with the rate of cell division and mtDNA 
turnover, a cell-specific pressure on the mtDNA replication machinery. (Chan 
et al., 2013; Miller et al., 2003). The minimal mtDNA replisome in vitro 
includes POLG, TWNK and SSBP1, but several other enzymes are involved in 
mtDNA replication in vivo (Korhonen et al., 2004). These include enzymes for 
dNTP synthesis, topoisomerase to relieve torsional stress and RNA 




Figure 5 Mitochondrial DNA and mitochondrial translation machinery. MtDNA encodes 
subunits of the OXPHOS, tRNAs and rRNAs, which are transcribed as a 
polycistronic RNA product and processed to give rise to different RNA species. The 
functional RNAs are used in the translation of subunits of the OXPHOS complexes 
by mitochondrial ribosomes (green balls). The translation is coupled with insertion 
of the synthesised protein into a functional complex. 
The current understanding of mtDNA replication is not complete, and 
different replication models have been proposed. In the strand-displacement 
model, replication initiates in the D-loop and continues until the origin of the 
light strand replication is reached, which initiates the replication of the light 
strand to the opposite direction (Clayton, 1982). This was initially proposed as 
the model for mtDNA replication due to detection of single-stranded 
replication intermediates in electron micrographs (Clayton, 1982; Robberson 
et al., 1972). An alternative model suggests that mtDNA is replicated through 
a conventional strand-coupled mechanism. This is supported by detection of 
double-stranded mtDNA replication intermediates, which can be separated by 
two-dimensional agarose gel electrophoresis (Holt et al., 2000). Also, 
detection of multiple lagging strand initiation sites further supports this model 
of mtDNA synthesis (Brown et al., 2005). Later discoveries revealed that the 
lagging strand can be synthesised first as RNA, which is subsequently matured 
into DNA (Yasukawa et al., 2006). 
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2.2 MITOCHONDRIAL DNA MAINTENANCE ENZYMES 
2.2.1 MITOCHONDRIAL TRANSCRIPTION FACTOR A 
Nuclear DNA is compactly packed into nucleosomes, which are histone 
complexes wrapped with DNA. Similar nucleosome-like structures exist in 
mitochondria since the ~5 µm long mtDNA cannot exist as a free molecule 
within a typical mitochondrion (Kukat and Larsson, 2013; Nass, 1969).  These 
structures containing proteins and DNA are called nucleoids, and they are 
likely to be attached to the inner mitochondrial membrane. A critical protein 
for the packaging of mtDNA into nucleoids is mitochondrial transcription 
factor A (TFAM), which can bind, bend and unwind mtDNA without sequence 
specificity (Fisher et al., 1992). One nucleoid is estimated to have only one copy 
of mtDNA, but the complete protein composition of the mitochondrial 
nucleoid is still under investigation (Kukat et al., 2011). In addition to TFAM, 
nucleoids consist of enzymes of the mitochondrial replication and 
transcription machineries (Bogenhagen et al., 2008; Bogenhagen et al., 2003). 
TFAM is an essential protein in mtDNA maintenance since knocking it out 
from mouse leads to loss of mtDNA copy number and embryonic lethality 
(Larsson et al., 1998). Overexpressing TFAM in mouse increases mtDNA copy 
number indicating that TFAM regulates mtDNA copy number in vivo 
(Ekstrand et al., 2004). 
TFAM also functions as a transcription factor (TF), and it is an 
indispensable factor in the expression of mtDNA (Fisher and Clayton, 1988; 
Shi et al., 2012). The mitochondrial transcription machinery has been 
reconstituted in vitro and has three components: mitochondrial RNA 
polymerase (POLRMT), mitochondrial transcription factor B2 and TFAM 
(Falkenberg et al., 2002). Also, mtDNA replication in vivo is dependent on 
TFAM as the synthesis of RNA primers is catalysed by the transcription 
machinery (Fuste et al., 2010). 
2.2.2 DNA POLYMERASE GAMMA 
DNA polymerases replicate DNA for transmission of genetic material to 
daughter cells. The replication of nuclear DNA is mediated by several different 
DNA polymerases, but DNA polymerase gamma (POLG) is thought to be the 
main mitochondrial DNA polymerase (Bolden et al., 1977). POLG is a 
heterotrimeric enzyme consisting of one catalytic subunit (POLG) and two 
accessory subunits (POLG2), which regulate the processivity of the enzyme 
complex (Yakubovskaya et al., 2006). Abolished POLG expression in mouse is 
embryonically lethal due to depletion of mtDNA copy number between 
embryonic days E7.5-E8.5 suggesting that no other polymerase has redundant 
mtDNA replicative activity during embryogenesis (Hance et al., 2005). 
The catalytic subunit, POLG, consists of three main domains: polymerase 
domain, exonuclease domain and the spacer region, which connects the two 
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catalytic domains. The crystal structure of POLG revealed that the spacer 
region is critical in binding the two accessory subunits (Lee et al., 2009). This 
feature provides an exceptionally high polymerase processivity compared to 
the other members of the Pol I family, which lack the spacer region (Lee et al., 
2009). POLG also has exceptional fidelity due to intrinsic 3’-5’ exonuclease 
and 5’-deoxyribose phosphate (dRP) lyase activities (Lim et al., 1999; Longley 
et al., 1998a; Longley et al., 1998b). Yeast, Drosophila and mouse mutants 
lacking POLG proof-reading activity accumulate mtDNA point mutations and 
show signs of premature ageing (Bratic et al., 2015; Foury and Vanderstraeten, 
1992; Trifunovic et al., 2004). 
The role of mtDNA repair has not been vastly investigated to date, and 
therefore, its significance in mitochondrial function and disease is still not 
fully understood. The best characterised mode of repair is base excision repair, 
which has been suggested to be the main repair pathway in mitochondria 
(Kazak et al., 2012). The recognition and cleavage of a damaged base is 
catalysed by DNA glycosylases, e.g. UNG1 and MYH, which are targeted to 
mitochondria (Nakabeppu, 2001; Nilsen et al., 1997; Slupphaug et al., 1993). 
Monofunctional DNA glycosylases leave a 5’-terminal dRP sugar in the cleaved 
site, which needs to be removed before gap filling. This is catalysed by POLG 
dRP-lyase activity (Longley et al., 1998a). After processing, the gap is filled by 
POLG, and the damage is repaired preventing a point mutation from 
occurring. 
2.2.3 TWINKLE HELICASE 
Mitochondrial helicase Twinkle was found in 2001 when Spelbrink et al. 
reported mitochondrial localisation of a phage T7 gene 4-like primase/helicase 
encoded by TWNK (Spelbrink et al., 2001). TWNK forms hexameric ring 
structures and unwinds double-stranded DNA, but despite the homology 
between phage T7 primase/helicase, TWNK has lost its primase function in 
mammals (Korhonen et al., 2003; Shutt and Gray, 2006). The RNA primers 
for initiation of mtDNA synthesis in mammals are synthesised by 
mitochondrial RNA polymerase (POLRMT) (Fuste et al., 2010; Wanrooij et al., 
2008). 
The evidence suggests that TWNK works as a licensing factor in mtDNA 
replication initiation since the amount of TWNK highly correlates with 
mtDNA copy number, and the overexpression of TWNK increases mtDNA 
copy number in muscle, heart and brain in mice (Tyynismaa et al., 2004; 
Ylikallio et al., 2010). This is further supported by a study which reports 
induced mtDNA replication and enlarged nucleoids in mice overexpressing 
TWNK  (Ylikallio et al., 2010). 
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2.3 GENOMIC REGULATION OF MTDNA MAINTENANCE 
PROTEINS 
2.3.1 REGULATORY ELEMENTS OF NUCLEAR DNA 
The control of gene expression is a complex interplay between transcriptional 
and post-transcriptional regulatory mechanisms forming a unique regulatory 
network to control the expression of each gene. There are circa 20,000 genes 
in the human genome, but only a limited number of them is expressed 
simultaneously (Collins et al., 2003). The set of expressed genes in a cell 
defines its structure and functions forming specialised cell types, or more 
broadly, different tissues. Some genes work as housekeeping genes and are 
required for the basic metabolism of the cell and, therefore, need to be 
continuously expressed. On the other hand, the expression of some genes is 
restricted to a specific tissue at a certain time point requiring strict temporal 
and spatial control (Goldhamer et al., 1995). These highly specific 
requirements for gene expression are achieved by multilevel regulatory stages. 
Recent advances in DNA sequencing methods have provided an excellent 
base for comparative genomics and have also allowed methodological 
development for genome-wide analyses of the chromatin state across different 
species and tissues. Genome-wide approaches were used in the encyclopedia 
of DNA elements (ENCODE) project, which in consortium performed several 
state-of-the-art experiments with a large set of tissues and cell lines to 
characterise genomic DNA elements and chromatin structure (Consortium, 
2012). This work included genome-wide analysis of transcription factor 
binding sites (TFBSs), DNA methylation profiles, DNase I hypersensitive sites 
(DHSs) and RNA sequencing (Consortium, 2012). All ENCODE data sets are 
available online for the research community and were also utilised in this 
thesis. 
2.3.1.1 Proximal promoter 
The initiation of transcription takes place in the promoter, which provides a 
docking site for the transcription machinery in the immediate upstream region 
of the transcription start site. Mammalian promoters contain various 
conserved sequence elements, which are recognised and bound by TFs. The 
TFs in the proximal promoters can induce or repress gene expression or 
provide binding sites for distal regulatory elements functioning in cis usually 
leading to more fine-tuned gene regulation, e.g. tissue-specificity of 
transcription (Carey and Smale, 2000; Perkins et al., 1996). 
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2.3.1.2 Distant-acting regulatory elements 
The recruitment of RNA polymerase to proximal promoter and its release to 
initiate transcription is often regulated by distal DNA sequences, which are 
called enhancer elements. These elements are DNA sequences that are 
recognised and bound by TFs, which form DNA-protein interactions. The 
enhancer-bound TFs can in unison activate gene transcription independent of 
the orientation, distance or location of the enhancer element in respect to the 
target gene (Banerji et al., 1981). Some enhancers are even known to regulate 
genes located in other chromosomes (Geyer et al., 1990). 
The exact mechanisms how enhancer elements signal to the target 
promoter, are still under investigation. Recent development in microscopy 
and the discovery of chromosome conformation capture have revealed that an 
enhancer element and the target promoter are commonly brought to close 
proximity by DNA looping (Figure 6) (Dekker et al., 2002). These interactions 
are, however, transient and the dynamic nature of chromatin state poses 
challenges in interpreting data regarding the mechanisms of gene regulation. 
In some cases, the looping of DNA for enhancer-promoter interaction is 
achieved by the function of the mediator complex, which is a co-activator 
complex consisting of approximately 30 subunits (Kagey et al., 2010). It 
signals between the enhancer and transcription machinery via the interaction 
with site-specific factors and RNA polymerase of the proximal promoter 
(Kagey et al., 2010; Malik and Roeder, 2010). Alternative modes of action are 
also reported to mediate enhancer function.  For example, the 
phosphorylation of serine at amino acid position 10 of histone H3 in an 
enhancer triggers a cascade where an adaptor protein, 14-3-3, binds the 
phosphorylated histone and recruits a histone acetyltransferase. The histone 
acetyltransferase can further modify the epigenetic landscape of the 
surrounding genomic locus activating the transcription of the target gene, 
FOSL1 (Figure 6) (Zippo et al., 2009). 
Genome-wide studies have characterised the landscape of the genomic 
regulatory elements in detail identifying the regulatory regions of more than 
100 different cell and tissue types (Consortium, 2012). However, these studies 
were mostly conducted in cell lines or by using whole-tissue homogenates and 
identified relatively general regulators and did not find elements that drive 
expression in highly restricted cell populations. Therefore, in silico predictions 
of regulatory elements and their validation in vivo is needed to identify 
elements with highly spatially restricted function (Hallikas et al., 2006). 
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Figure 6 Gene regulation mechanisms by lncRNAs and enhancer elements. (A) Enhancer 
elements create DNA loops to bring chromatin structures to close proximity. 
LncRNA (purple dashed line) acts as a protein scaffold to recruit transcription 
machinery to the proximal promoter to initiate RNA synthesis. (B) Enhancers can 
modify the epigenetic landscape of chromatin regions to active or (C) repress gene 
expression. 
2.3.2 LONG NON-CODING RNAS REGULATE GENE EXPRESSION 
Long non-coding RNAs (lncRNAs) are generally defined as > 200 bp long RNA 
transcripts that do not encode proteins but regulate the expression of other 
genes (Rinn et al., 2007; Rutenberg-Schoenberg et al., 2016). LncRNAs are, 
similarly to protein coding genes, transcribed by Pol II, spliced, capped and 
polyadenylated but are not translated into protein and perform active 
functions as RNA molecules. The classification of lncRNAs, however, is 
problematic since the general definition of lncRNAs is negative, i.e. the lack of 
protein coding property is used as an inclusion criterion. However, long RNA 
transcripts are likely to have, even by chance, stretches that have start and stop 
codons and can theoretically encode proteins that are > 100 amino acids long. 
Also, some RNAs can act as coding transcripts and have dual roles as 
regulatory RNAs the functions of which are independent of translation (Hube 
et al., 2006). To evaluate the potential of an RNA transcript to encode a 
protein, different comparative and experimental approaches can be used. In 
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contrast to genes encoding functional RNAs, protein coding genes often have 
a strong selection against variants that change the protein sequence (missense 
or frameshift variants), and they often contain conserved structural domains 
(Yang and Bielawski, 2000). In addition, a recently developed method to study 
RNA molecules that are bound by ribosomes (ribosomal footprint profiling) 
and are, therefore, translated into proteins, is useful for experimentally 
identifying lncRNAs by revealing protein-coding RNA transcripts (Guttman et 
al., 2013). 
The functional roles of lncRNA are diverse, and new mechanistic insight 
into biochemical activities of lncRNAs are constantly discovered (Tay et al., 
2014). In general, lncRNAs (1) act locally at the sites they are transcribed or 
(2) function in trans and regulate chromatin state at sites that are independent 
of the transcription site of the lncRNA. However, this classification is not 
exhaustive and many lncRNAs fall in between these classifications (Dimitrova 
et al., 2014; Huarte et al., 2010). 
The flagship example in the field of lncRNAs is the X chromosome 
inactivation by Xist. In females, the expression of one of the two X 
chromosomes is repressed balancing the expression of the chromosome in 
females and males. The search for the factor mediating this inactivation led to 
the discovery of a large transcript (~18 kb in mice) that was first considered to 
be a protein-coding mRNA but eventually was found to be a functional RNA 
and the master regulator of X chromosome inactivation (Gendrel and Heard, 
2014; Lee, 2009). The Xist transcript spreads along one of the X chromosomes 
coating the majority of the chromosome and eventually leading to major 
chromatin remodelling, which includes histone modifications and DNA 
methylation leading to silencing of the whole chromosome (Plath et al., 2003). 
As mentioned above, lncRNAs can also act locally near the site of their 
transcription and assemble with protein complexes (Mao et al., 2011). These 
protein complexes are often chromatin modifying proteins that activate or 
repress gene expression (Brockdorff, 2013). One early example of locally 
acting lncRNAs is Airn, which was originally thought to suppress the 
expression of the antisense gene Igf2r by recruiting chromatin modifying 
factors (Wutz et al., 1997). Functional studies, however, indicated that the 
RNA sequence of Airn was not critical for silencing of Igf2r, but the act of its 
transcription as an antisense strand was found to drive the suppression of the 
target gene (Latos et al., 2012). This example showed that the sequence of 
lncRNAs can be dispensable and underscores the need of critical evaluation of 
the biochemical properties and functional mechanisms of lncRNAs. 
2.3.3 REGULATORY REGIONS AND DISEASE 
Recent advances in high-throughput sequencing have led to the discoveries of 
thousands of genetic variants that modify common diseases, such as diabetes 
and Alzheimer’s disease, and normal human phenotypes, e.g. circulating 
metabolite levels (Billings and Florez, 2010; Kettunen et al., 2016; Lambert et 
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al., 2013). Many of these variants are located outside the protein-coding 
regions indicating that they might affect gene expression. Also, mutations 
disturbing gene regulation are known to underlie many human disorders, and 
a few examples are presented in this chapter.  
Mutations in enhancer regions lead to reduced expression of the target 
genes in specific cells causing highly tissue-specific manifestations (Smith and 
Shilatifard, 2014). One example of such case is a form of beta-thalassemia, 
which is a disease caused by insufficient synthesis of beta-chains of 
haemoglobin resulting in severe anaemia (Williams and Weatherall, 2012). A 
subset of beta-thalassemia patients was found to carry a large deletion 
upstream of the beta-globin gene, HBB, which did not affect its coding region 
(Kioussis et al., 1983; Van der Ploeg et al., 1980). DNase I hypersensitive 
experiments and reporter studies revealed this region to be a complex 
regulatory region, which drives the expression of HBB for haematopoiesis. 
Also, translocation of a gene to the vicinity of a strong enhancer region can 
have detrimental consequences since the expression of the gene will be 
ectopically activated or increased in cells that normally do not express the gene 
or express it at low level. In Burkitt’s lymphoma MYC is translocated to the 
chromosomal region where immunoglobulin is encoded (Haluska et al., 1986). 
The enhancer element in the region activates MYC expression, and since MYC 
is an oncogenic TF, the patients develop B cell lymphomas. Transgenic mice 
carrying Myc linked to the immunoglobulin enhancer also develop B cell 
malignancies indicating the causal role of the MYC translocation for the cancer 
in Burkitt’s lymphoma patients (Adams et al., 1985). 
Mutations in proteins which regulate or mediate the enhancer function, can 
also disturb gene regulation leading to human pathologies. Patients with 
Cornelia de Lange syndrome carry mutations in SMC1, SMC3 or NIPBL, which 
all are subunits of the cohesin complex that has a role in the enhancer-
promoter communication but also functions in chromosome segregation. This 
dual role of the cohesin complex raises the question, which of the functions is 
affected in the patient? Mutations in NIPBL are commonly found in the 5’ 
untranslated region (UTR) affecting the expression of the gene (Borck et al., 
2006). The human symptoms develop when NIPBL transcript level is reduced 
to 85%, but the chromosome segregation can still occur when only 13% of WT 
NIPBL is present. This indicates that Cornelia de Lange syndrome is likely to 
be caused due to defective enhancer-promoter communication (Dorsett and 
Krantz, 2009; Liu and Krantz, 2008). 
2.3.4 REGULATORS OF NUCLEAR ENCODED MITOCHONDRIAL 
PROTEINS 
The structure and number of mitochondria vary in different tissues depending 
on the metabolic and energetic needs of the tissue. The mitochondrial network 
is also highly dynamic, adapts to cellular requirements and responds to 
external stimuli by changing mitochondrial mass, morphology and gene 
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expression. Known inducers of mitochondrial function and biogenesis are, for 
example, stem cell differentiation and different physiological stimuli, e.g. 
exercise and thermogenesis in muscle and brown adipose tissue, respectively 
(Cuezva et al., 1997; Enriquez et al., 1999; Hood, 2001; Klingenspor et al., 
1996). Furthermore, mitochondrial dysfunction is known to induce 
mitochondrial mass in specific muscle fibres, RRFs, which are used as a 
diagnostic marker of mitochondrial disorders. These observations show that 
mitochondrial mass is under spatio-temporal regulation, and a complex 
regulatory circuit is needed to coordinate the expression of the mitochondrial 
proteome, which consists of approximately 1200 proteins (Calvo et al., 2016). 
A few activators and co-activators have been identified to induce the 
transcription of nuclear-encoded mitochondrial proteins, and these regulators 
include peroxisome proliferator-activated factors (PPARs), nuclear 
respiratory factors (NRFs) and estrogen-related receptors (ESRRs). ESRRs 
family members, ESRRA and ESRRB, resemble the estrogen receptor but do 
not bind estrogen or other ligands but regulate the expression of respiratory 
complex subunits (Mootha et al., 2004; Schreiber et al., 2004; Sladek et al., 
1997).  
NRF-1 and NRF-2 are TFs that are known to regulate many nuclear genes 
targeted to mitochondria. They were originally identified to bind to the 
regulatory regions of cytochrome c (NRF-1) and cytochrome c oxidase (NRF-
2) subunit genes, but since then, they have been shown to have a broad role in 
the regulation of mitochondrial metabolism and especially in the regulation of 
the subunits of respiratory complexes (Evans and Scarpulla, 1989; Scarpulla, 
1997, 2008). Interestingly, NRF-1 and NRF-2 also regulate the expression of 
human TFAM, TFB1M and TFB2M and, thereby, links the expression of 
nuclear and mitochondrial genomes (Gleyzer et al., 2005; Virbasius and 
Scarpulla, 1994). The targets of NRF-1 and NRF-2 are not, however, restricted 
to respiratory chain subunits or mtDNA transcription, but they also regulate 
mitochondrial import machinery and the assembly factor of mouse 
cytochrome c oxidase, COX17 (Blesa et al., 2007; Takahashi et al., 2002). 
Importantly, the NRFs also regulate genes with no association to 
mitochondrial function but encode metabolic enzymes, components of 
signalling pathways and gene products necessary for nucleic acid metabolism 
(Virbasius et al., 1993). The regulatory role of NRF-1 on these pathways is 
likely to underlie the embryonal lethality of NRF-1 knock-out mice (Huo and 
Scarpulla, 2001). 
The PGC-1 family consists of three transcriptional coactivators: peroxisome 
proliferator-activated receptor-gamma coactivators, PGC-1α and PGC-1β, and 
PGC-1 related coactivator (PRC). These factors have been shown to induce 
mitochondrial biogenesis by binding TFs and nuclear receptors with specific 
DNA sequence binding properties (PGC-1 binding partners reviewed by 
(Villena, 2015)). The members of the PGC-1 family lack histone acetyl 
transferase activity, which can remodel chromatin state, but the PGC-1 factors 
induce gene transcription by binding and recruiting other proteins with 
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histone acetyl transferase activity, such as SRC-1 and CBP/p300, to the target 
promoters (Puigserver et al., 1999) 
2.3.4.1 Expression Regulation of mtDNA Maintenance Genes 
The transcription regulation of mtDNA maintenance genes is not 
comprehensively studied. Only few reports have characterised the genomic 
loci of these genes and they solely focus on POLG regulation. 
POLG is located in chromosome 15 and is encoded by 23 exons, which span 
over 18.5 kilo base pair (kb) long region. The homology of the exons between 
mouse and human ranges from 71% - 95% (Mott et al., 2000).  The promoter 
region is predicted to locate directly upstream from the transcription start site 
and this region shares 74% homology between mouse and human (Mott et al., 
2000). The putative promoter does not have a TATA box sequence or 
predicted binding sites for known transcription regulators of mitochondrial 
metabolism e.g. NRF1 or PGC-1alpha (Mott et al., 2000). 
POLG exon 2 has been reported to be methylated, which downregulates 
POLG expression. The methylation level was suggested to be associated with 
mtDNA copy number regulation (Kelly et al., 2012).  
2.4 MTDNA MAINTENANCE DISORDERS 
Mitochondrial dysfunction underlies a catalogue of human disorders, which 
can present at any age and affect many organs or show highly tissue-specific 
manifestation (Ylikallio and Suomalainen, 2012). The reason why specific 
tissues are sensitive to particular gene defects, is currently not well 
understood, and the question has puzzled the mitochondrial disease field for 
decades. The genetic background of mitochondrial disorders is diverse, and 
causative mutations are found in mtDNA or in nuclear genes encoding 
mitochondrial proteins (Wallace et al., 1988; Zeviani et al., 1990). The nuclear 
gene defects most commonly affect the structural proteins of respiratory chain, 
mitochondrial translation, proteins involved in mitochondrial dynamics or 
mtDNA maintenance. The focus of this thesis is mtDNA replication defects, 
with the emphasis on POLG and TWNK. Defects in these genes are the most 
common causes of mitochondrial disorders and prime examples of tissue- and 
genotype-specific variability of manifestations: different mutations in POLG 
and TWNK can either lead to severe infantile neurodegeneration or adult-
onset MM. The underlying cause of these disorders is generally thought to be 
secondary mtDNA instability in affected tissues leading to accumulation of 
multiple mtDNA deletions or depletion of mtDNA copy number. 
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2.4.1 POLG DISORDERS 
The mtDNA replicative polymerase, POLG, is the most common nuclear gene 
underlying mitochondrial disorders. An exceptionally large number of 
pathogenic mutations have been found in POLG and they are listed in the 
POLG disease mutation database (http://tools.niehs.nih.gov/polg/). POLG 
diseases typically manifest in the nervous system but can also affect the liver 
and muscle (Lamantea et al., 2002; Suomalainen and Isohanni, 2010). Despite 
the apparent requirement of mtDNA replication in cell division, the patients 
with POLG disorders do not typically show symptoms of highly proliferating 
cell types, such as blood or intestinal cells. The main clinical syndromes caused 
by POLG mutations are PEO, Alpers-Huttenlocher syndrome and 
mitochondrial recessive ataxia-polyneuropathy syndrome (MIRAS, MSCA-E, 
SANDO) (Hakonen et al., 2005; Naviaux et al., 1999; Van Goethem et al., 
2001; Winterthun et al., 2005). 
Alpers syndrome is typically caused by recessive POLG defects leading to 
tissue-specific mtDNA depletion and affects patients in early infancy (Alpers, 
1931; Naviaux and Nguyen, 2004). The patients develop psychomotor 
retardation, liver failure and epileptic seizures typically leading to premature 
death before 10 years of age (Young and Copeland, 2016). 
PEO can be caused by dominant or recessive POLG mutations and is 
characterised by accumulation of multiple mtDNA deletions in post-mitotic 
tissues. PEO manifests with bilateral ptosis and progressive weakening of the 
extraocular muscles (EOMs), generalised muscle weakness and exercise 
intolerance. POLG-PEO patients also present often with sensory neuropathy 
and early-onset parkinsonism (Luoma et al., 2004; Van Goethem et al., 2001).  
POLG-related ataxia-polyneuropathy syndrome, MIRAS, typically 
presents in childhood or early adulthood. It is most often caused by 
homozygous or compound heterozygous p.W748S and p.A467T changes 
(Hakonen et al., 2005; Rantamaki et al., 2001; Winterthun et al., 2005). The 
clinical symptoms of MIRAS include gait ataxia, sensory neuropathy and some 
patients also develop epileptic seizures. Remarkably, patients with identical 
MIRAS mutations show high variability in clinical presentations indicating 
strong contribution of environmental or genetic modifiers. 
2.4.2 TWNK DISORDERS 
Dominant mutations in TWNK manifest as adult-onset PEO with progressive 
accumulation of multiple mtDNA deletions in patients’ tissues (Spelbrink et 
al., 2001). Recessive TWNK defects, however, cause infantile-onset 
spinocerebellar ataxia (IOSCA), and the patients do not show clinical muscle 
symptoms (Hakonen et al., 2008; Hakonen et al., 2007; Nikali et al., 2005). 
IOSCA manifests after one year of age with progressive ataxia, peripheral and 
optic neuropathy, hearing loss and athetosis. In juvenile age, the patients 
develop female hypergonadotropic hypogonadism, severe epilepsy, 
psychiatric symptoms and hepatopathy (Koskinen et al., 1994a; Koskinen et 
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al., 1994b). IOSCA is the second most common inherited spinocerebellar 
ataxia in Finland and is caused by an ancestral homozygous founder mutation, 
leading to p.Y508C change (Nikali et al., 2005).  
2.4.3 MTDNA DEPLETION SYNDROME 
Depletion of mtDNA copy number leads to disrupted synthesis of the OXPHOS 
complexes causing tissue-specific or multi-tissue clinical manifestations 
(Moraes et al., 1991; Suomalainen and Isohanni, 2010). This genetically 
heterogeneous group of disorders is generally called mtDNA depletion 
syndrome (MDS), which is a common cause of childhood respiratory chain 
deficiencies (Sarzi et al., 2007). To date, 11 genes have been reported to 
underlie MDS, and the genetic background has provided insight into the 
mechanisms essential for mtDNA maintenance. No evidence is invoking 
reduced mtDNA half-life in MDS suggesting that the depleted mtDNA copy 
number is caused by insufficient mtDNA replication. 
Many genes underlying MDS are directly involved in maintaining the 
cellular dNTP pools. These genes are thymidine kinase 2 (TK2), 
deoxyguanosine kinase (DGUOK), ribonucleotide reductase regulatory TP53 
inducible subunit M2B (RRM2B) and thymidine phosphorylase (TYMP) 
(Bourdon et al., 2007; Mandel et al., 2001; Nishino et al., 1999; Papadimitriou 
et al., 1998; Saada et al., 2001). Defects in these genes are thought to 
compromise dNTP de novo synthesis or dNTP salvage pathways affecting total 
cellular and mitochondrial dNTP pools (Spinazzola et al., 2009). TYMP 
mutations are suggested to increase the cellular dTTP pool causing indirect 
deoxycytidine triphosphate dCTP depletion and, thereby, accounting for the 
mtDNA depletion (Lopez et al., 2009). 
Mutations in ATP-specific succinyl-CoA synthethase beta (SUCLA2) and 
GTP-specific succinyl-CoA synthethase beta (SUCLG2) are also likely to cause 
MDS by defects in dNTP pool maintenance since they are part of the succinyl 
coA synthase complex, which associates with mitochondrial nucleoside 
diphosphate kinase (Elpeleg et al., 2005; Ostergaard et al., 2007). Recently, a 
novel MDS gene was discovered when mutations in ABAT were found from 
MDS patients (Besse et al., 2015). ABAT encodes 4-aminobutyrate 
aminotransferase, which physically interacts with SUCLG1, SUCLG2 and 
SUCLA2. The mtDNA depletion caused by ABAT mutations can be rescued by 
dNTP supplementation in cultured cells suggesting insufficient dNTP 
concentration in ABAT patient cell lines  (Besse et al., 2015). 
The most recently discovered genetic defect underlying MDS was found 
from patients manifesting with a severe myopathy and lactic acidosis in early 
childhood. These patients carry de novo dominant mutations in adenine 
nucleotide translocator (SLC25A4) (Thompson et al., 2016). The mutations 
locate in the conserved functional domain of the protein, whereas the earlier 
reported mutations in SLC25A4 causing autosomal dominant PEO are found 
from non-conserved region of SLC25A4 and cause a less severe enzyme defect. 
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Three additional genes are known to cause MDS, but they are not directly 
involved in dNTP pool maintenance. These genes are POLG, TWNK and 
MPV17. MPV17 is a mitochondrial protein with an unknown function, but its 
mutations are identified from MDS families. Interestingly, a recent study of 
MPV17 knock-out mice found low dTTP and dGTP pools in liver associated 
with mtDNA depletion and slow mtDNA replication (Dalla Rosa et al., 2016). 
These findings were also replicated in patient fibroblasts indicating that 
MPV17 is essential for dNTP pool maintenance through an unknown 
mechanism. POLG and TWNK are the key enzymes in mtDNA replication 
catalysing the synthesis of mtDNA and unwinding mtDNA double helix 
structure, respectively (Hakonen et al., 2008; Naviaux and Nguyen, 2004). 
POLG and TWNK defects are thought to be direct synthesis defects, but 
whether they cause secondary dNTP pool disturbance, has not been 
experimentally addressed.  
The two mechanisms behind MDS, decreased dNTP availability and 
defective mtDNA synthesis, are generally accepted models for mtDNA 
depletion. MDS most commonly causes mtDNA depletion only in post-mitotic 
tissues where mtDNA is actively synthesised, but nuclear DNA is not 
replicating. Post-mitotic cells, therefore, synthesise dNTPs mainly to support 
the replication of the mitochondrial genome, which requires much less dNTPs 
than nuclear DNA synthesis. This sensitises post-mitotic cells to defects in 
dNTP synthesis enzymes which underlie mtDNA depletion. 
2.4.4 THE GENETIC BACKGROUND OF MTDNA DELETIONS 
Accumulation of mtDNA deletions is another underlying cause of 
mitochondrial disorders. Single mtDNA deletions are typically sporadic or 
maternally inherited, and they are always heteroplasmic. The proportion of 
single deletions varies between tissues and can change over time. More 
typically, a genetic defect leads to the accumulation of multiple mtDNA 
deletions. The deletions commonly occur in the region between the origins of 
replication of the light and heavy strands (Samuels et al., 2004). The genes 
underlying human disorders with mtDNA deletions are heterogeneous and 
partially overlapping with genes causing mtDNA depletion described above. 
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Table 1. Gene defects underlying mtDNA deletions in human disorders. The table is 
adapted from (Viscomi and Zeviani, 2017). Abbreviations: ad, autosomal 
dominant; ar, autosomal recessive 
Gene Defect Inheritance Clinical syndrome Reference 
POLG ad/ar PEO/MIRAS (Van Goethem et al., 
2001), (Winterthun et 
al., 2005), (Hakonen et 
al., 2005) 
POLG2 ad PEO (Longley et al., 2006) 
TWNK ad/ar PEO (Spelbrink et al., 2001) 
OPA1 ad PEO (Amati-Bonneau et al., 
2008), (Hudson et al., 
2008) 
RRM2B ad PEO (Tyynismaa et al., 
2009) 
SLC25A4 ad PEO (Kaukonen et al., 
2000) 
TYMP ar MNGIE (Nishino et al., 1999) 
MGME1 ar PEO (Kornblum et al., 2013) 
DNA2 ar PEO (Ronchi et al., 2013) 
GFER ar myopathy (Di Fonzo et al., 2009) 
RNASEH1 ar PEO (Reyes et al., 2015) 
TK2 ar PEO (Tyynismaa et al., 
2012) 
SPG7 ar PEO/ataxia (Pfeffer et al., 2014) 
AFG3L2 ad PEO/ataxia (Gorman et al., 2015) 
DGUOK ar PEO (Ronchi et al., 2012) 
MPV17 ar PEO/ 
leukoencephalopathy
(Blakely et al., 2012) 
 
2.5 MOUSE MODELS WITH COMPROMISED MTDNA 
INTEGRITY 
2.5.1 DELETOR MOUSE – MODEL FOR MITOCHONDRIAL MYOPATHY 
Deletor mouse is a model for mitochondrial myopathy (MM). The mice carry 
a TWNK transgene under the human ACTB promoter ubiquitously expressing 
a dominant TWNK patient mutation, duplication of amino acids 353-365 
(Tyynismaa et al., 2005). The TWNK defect leads to generation and 
progressive accumulation of mtDNA deletions in muscle and brain starting at 
12 months of age. This is coupled with abnormal mitochondrial ultrastructure 
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and cytochrome c oxidase (COX)-deficiency in 5-10% of Deletor muscle fibers 
by the age of 24 months (Tyynismaa et al., 2005). These key features replicate 
the signs of the patient disease making Deletor mouse an invaluable tool for 
studying the mechanisms of MM with multiple mtDNA deletions 
(Suomalainen et al., 1992; Zeviani et al., 1989). 
The progressive respiratory chain deficiency in Deletor mice is suggested 
to compromise the oxidation of NADH to NAD+ causing decreased cellular 
NAD+ concentration (Khan et al., 2014). To correct this, Khan et al. 
supplemented the mice with an NAD+ precursor, nicotinamide riboside (NR), 
which increased the cellular NAD+ levels and reverted the disease phenotype. 
The treatment decreased mtDNA deletion load, decreased the number of COX-
deficient muscle fibers and rescued the abnormal mitochondrial ultrastructure 
(Khan et al., 2014). The beneficial effect of NR is thought to be mediated by 
SIRT1 activation, which increases mitochondrial biogenesis. SIRT1 monitors 
the cellular NAD+/NADH ratio and deacetylates FOXO1 when cellular 
NAD+/NADH ratio is increased (Canto et al., 2012; Rodgers et al., 2005). This 
activates mitochondrial biogenesis, fatty acid oxidation and mitochondrial 
ATP production. Other studies have also reported beneficial effects of NR 
supplementation in mouse models with mitochondrial dysfunction: NR 
alleviated muscle pathology in a mouse model which carries p.W129K change 
in SCO2 corresponding to the patient p.E140K mutation (Cerutti et al., 2014; 
Yang et al., 2010). Together, these studies suggest that NR supplementation 
has high potential in treatment of MM. 
The mtDNA replication defect and consequent mtDNA deletions in Deletor 
mice also induce a transcriptional response in the nucleus, which potentially 
modifies disease progression by activating or deactivating intracellular 
metabolic pathways and by causing systemic metabolic changes (Tyynismaa et 
al., 2010). One gene that shows increased expression in Deletor muscle is 
Fgf21, which is a hormone that was first identified to be secreted from liver 
during fasting to mobilise lipids from white adipose tissue (Badman et al., 
2007; Kharitonenkov et al., 2005). In mice with MM, however, FGF21 can also 
be secreted from muscle (Kim et al., 2013; Tyynismaa et al., 2010). Consistent 
with FGF21 effects on body composition, increased circulating FGF21 in 
Deletors is associated with decreased body fat and reduced liver fat content 
(Tyynismaa et al., 2010; Tyynismaa et al., 2011). 
FGF21 is also increased in the plasma of PEO patients and other 
mitochondrial patient groups, and it was further shown to be a sensitive and 
specific marker for mitochondrial disease (Davis et al., 2013; Fujita et al., 
2015; Salehi et al., 2013; Suomalainen et al., 2011). Recently, increased plasma 
FGF21 level was associated to gene defects causing mitochondrial translation 
problem but not to defects that cause primary respiratory chain dysfunction 
(Lehtonen et al., 2016). 
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2.5.2 MUTATOR MOUSE 
POLG is a high-fidelity polymerase due to its exonuclease activity, which 
recognises falsely inserted nucleotide during replication and excises it before 
replication can continue. This ensures faithful replication of mtDNA and 
prevents transmission of mutations to the daughter molecule. Abolishing the 
POLG exonuclease function in mice induces generation and accumulation of 
mtDNA point mutations in all tissues leading to a premature ageing-like 
phenotype (Trifunovic et al., 2004). These knock-in “Mutator” mice manifest 
with kyphosis, osteoporosis, low body weight, decreased adipose tissue and 
thinning of the skin. The mice also develop progressive megaloblastic anaemia 
leading to early death around 13-15 months. 
The Mutator mouse, together with an extensive field of research, has 
discounted the mitochondrial theory of ageing which states that the generation 
of mtDNA point mutations potentially leads to a vicious cycle by inducing ROS 
generation (Sanz, 2016). ROS is a potent DNA damaging agent which could 
induce further generation of mtDNA lesions. The Mutator mouse, however, 
does not show exponential generation of point mutations, but the driving force 
behind the ageing phenotype of the mouse is thought to be dysfunctional 
respiratory chain or defective mitochondrial translation (Edgar et al., 2009). 
2.5.3 MNGIE MOUSE 
Defects in genes critical for dNTP pool maintenance underlie a spectrum of 
mitochondrial disorders. One of these genes is TYMP whose mutations cause 
mtDNA deletions and depletion manifesting as mitochondrial 
neurogastrointestinal encephalopathy (MNGIE) (Nishino et al., 1999). TYMP 
degrades cellular dNTPs, and the loss of its activity causes increased thymidine 
(Thd) and deoxyuridine (dUrd) levels leading to dNTP pool imbalance and 
consequent loss of mtDNA integrity. TYMP knockout mouse (TYMP-/-) was 
created to study the MNGIE disease mechanisms and to test putative 
treatment strategies (Lopez et al., 2009). Since murine uridine phosphorylase 
(UPP1) can compensate for the loss of TYMP activity and degrade Thd and 
dUrd, (TYMP-/-) mouse was crossed with UPP1 knock-out mice (UPP1-/-) to 
obtain TYMP/UPP1 double knockout (TYMP-/-, UPP1-/-) mice. The (TYMP-/-, 
UPP1-/-) mice recapitulate features of MNGIE patients and have increased Thd 
and dUrd levels in several tissues, including brain, muscle and small intestine  
(Lopez et al., 2009).  The increased Thd and dUrd levels lead to increased 
dTTP and decreased dCTP levels in the brain, which is thought to underlie the 
progressive loss of mtDNA copy number. The mice have 27% mtDNA 
depletion in brain at the age of 6 months and 61% depletion at 14-18 months, 
but no mtDNA deletions were detected. 
The elevation of Thd and dUrd in tissues of (TYMP-/-, UPP1-/-) mice is 
relatively modest (<65-fold) compared to MNGIE patients (>100-fold). This 
might explain the milder phenotype of the mice affecting mostly brain. 
Stressing the mice with long-term oral Thd and dUrd supplementation further 
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elevated their levels exacerbating the disease phenotype (Garcia-Diaz et al., 
2014). The treatment reduced the survival, body weight and motor functions 
of the mice and induced mtDNA depletion in the small intestine, which was 
accompanied with the loss of smooth muscle cells of the muscularis proparia 
(Garcia-Diaz et al., 2014). 
The dNTP pool imbalance in the (TYMP-/-, UPP1-/-) mice also leads to 
generation of mtDNA point mutations as the authors reported increased levels 
of C-to-T transitions in mtDNA, which have previously been observed also in 
MNGIE patients (Nishigaki et al., 2003). The   C-to-T transitions were detected 
frequently after a stretch of A residues, which indicates that they are induced 
by next-nucleotide effect. This suggests that dNTP imbalance can lead to 
generation of mtDNA point mutations even with intact POLG exonuclease 
activity (Lopez et al., 2009; Nishigaki et al., 2003). 
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3 AIMS OF THE STUDY 
The general aim of this thesis was to understand the molecular pathology and 
tissue-specificity of mtDNA maintenance diseases. The specific aims were as 
follows: 
 
To identify and characterise the metabolic response pathways in 
mitochondrial disease patients and mouse models with mtDNA replication 
defects. 
 
To find new treatment strategies for mtDNA maintenance disorders by 
modifying metabolic response pathways. 
 
To study the transcription regulation of mtDNA maintenance genes by 

























4 MATERIALS AND METHODS 
All methods are described in detail in the original publications and briefly 
presented here. 
4.1 ETHICAL STATEMENTS AND ANIMAL LICENSES 
The Ethical Review Board of Helsinki University Central Hospital approved 
the use and collection of human samples. The National Animal Review Board 
and Regional State Administrative Agency for Southern Finland approved the 
animal experiments used in this thesis, and they were conducted according to 
the European Union Directive. The animal experiments were performed under 
the following license number: ESAVI/689/04.10.07/2015. 
4.2 ANIMAL MODELS 
Deletor mice were previously described in (Tyynismaa et al., 2005). The mice 
express a dominant mutant TWNK with an in-frame duplication of amino 
acids 353-365 under ubiquitous ACTB promoter. The transgenic mice were 
maintained in C57BL/6 background. 
IOSCA mice were created by introducing the point mutation c.1526 A>G 
(p.Y509C) into a vector construct having frt-flanked neomycin (NEO) 
selection cassette together with homologous arms flanking the targeted region. 
The construct was electroporated into Sv129 mouse embryonic stem (ES) cells 
and introduced to the genome by homologous recombination. The positive ES 
cells were injected into C57BL/6 blastocysts. The NEO cassette was removed 
by crossing the IOSCA mouse with a mouse ubiquitously expressing Flp 
recombinase. The resulting mice were backcrossed to C57BL/6 by using speed 
congenic method utilising whole-genome single-nucleotide polymorphism 
(SNP) analysis. 
Enhancer regions and 250-300 bp flanking regions were amplified by 
polymerase chain reaction (PCR) and subsequently cloned into tkPD 
destination vector (gift from Jussi Taipale). The resulting constructs were 
linearised and injected into mouse zygotes to generate the enhancer founder 
lines. Polg promoter construct was created by cloning a region of 500 bp 
upstream from Polg transcription start site into tkPD vector without the 
minimal HSV-tk promoter. The primer sequences used for cloning the 
constructs can be found from the original articles. Staining patterns were 
considered real if the same pattern was detected in 3 founder lines. 
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4.3 HISTOLOGICAL STAININGS 
Enzyme activity stainings (COX and SDH) were performed as described in 
(Ahola-Erkkila et al., 2010). Freshly collected muscle samples were embedded 
with Tissue-Tek O.C.T.TM compound and frozen in isopentane cooled with 
liquid nitrogen. 
For immunohistochemistry and immunofluorescent staining, tissue-
samples were embedded into paraffin and sectioned. Paraffin was remove, and 
the tissue sections stained with standard protocols by using the following 
primary antibodies: pS6 (Cell signalling, #2217), Calbindin (Abcam, 
AB11426), β-Gal (Abcam, AB9361) and Islet1/2 (gift from Juha Partanen).  
4.4 MITOCHONDRIAL DNA ANALYSIS 
Total DNA was extracted by using phenol/chloroform extraction. The mtDNA 
copy number was analysed by quantitative PCR using SYBR Green and 
primers as in (Khan et al., 2014). MtDNA deletion load was analysed by triplex 
qPCR assay with 5’ modified probes with ROX (D-Loop probe), HEX (ND1 
probe) or FAM (ND4 probe) for the use in single-well detection (Rygiel et al., 
2015). 
4.5 ENHANCER ELEMENT PREDICTIONS 
Enhancer Element Locator version 1.5.2.2 was used in the predictions of 
enhancer elements. The coding region and 100 kb upstream and downstream 
of mtDNA maintenance genes was analysed in human, rat and mouse. 
Transcription factor binding site matrices provided by the program with added 
matrices for AHRARNT.01 and NFX_ARNT.01 (Genomatix) were the base of 
the analysis. 
4.6 LACZ STAINING 
Adult mice were perfused with ice-cold phosphate buffered saline (PBS) before 
tissue dissection. Mouse embryos were collected at E12.5, immersed in ice-
cold PBS and immediately dissected and washed once with phosphate buffer 
(0.1 M Na2HPO4, 0.1 M NaH2PO4). The embryos were fixed in fixing solution 
(0.2% glutaraldehyde, 5 mM EGTA, 2 mM MgCl2 in 0.1 M phosphate buffer) 
for 30 minutes at room temperature. Fixed samples were washed 3 x 15 
minutes in washing buffer (2 mM MgCl2, 0.01% DOC, 0.02% Nonidet P-40, 
0.1 M phosphate buffer) and stained in X-Gal staining solution (5 mM 
ferrocyanide, 5 mM ferricyanide, 1 mg/ml X-gal in washing buffer) at 37°C 
upon agitation until desired intensity was reached (minimum 3h). The stained 
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samples were rinsed 3 times with washing buffer and fixed in 4% 
paraformaldehyde (PFA) overnight at 4°C. 
4.7 METABOLOMICS ANALYSIS 
Metabolite measurements (“100-metabolites” and folate intermediates) were 
performed by Waters Acquity ultra performance liquid chromatography 
(UPLC) with triple-quadruple mass spectrometry (MS) detection. Detailed 
instrumentation and analytical conditions are described in the original 
articles. 
4.8 IN VIVO [U-13C]-GLUCOSE FLUX 
20 mg of [U-13C]-glucose (Cambridge Isotope Laboratories, catalogue no. 
CLM-1396) was administered to Deletor and WT mice via tail vein injection. 
The mice were sacrificed and tissues collected at 15 minutes. The samples were 
analysed by targeted selected reaction monitoring (SRM) liquid 
chromatography-tandem mass spectrometry [LC-MS/MS] on an Agilent 6460 
QQQ instrument. 
4.9  [18F]-FDG AND [18F]-FOLATE TRACER 
EXPERIMENTS 
Food was removed from mice four hours before the in vivo tracer experiments. 
The mice were anesthetised with isoflurane and a catheter was placed to the 
tail vein 15 minutes before intravenous administration of 5 MBq of [18F]-FDG 
or [18F]-folate. The mice were kept anesthetised for 60 minutes on 
temperature-controlled mats, and the activity of tissues was measured with a 
gamma counter. 
4.10 DNTP POOL MEASUREMENTS 
DNTP pools were measured from whole-tissue lysates using a sensitive 
polymerase-based assay. Detailed description of the method is described in 
(Nikkanen et al., 2016). 
4.11 QUANTITATIVE REAL-TIME PCR 
Total RNA was extracted from samples using Trizol reagent (Life 
Technologies, #15596-026).  1 µg of RNA was used in complementary DNA 
(cDNA) synthesis (Maxima First Strand cDNA synthesis kit, Thermo 
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Scientific, #K1672). Quantitative amplification of the target cDNAs was 
performed using iQ Sybr Green (Bio-Rad, #172-5006) on a CFX96 Touch Real-
Time PCR System (Bio-Rad). Actb was used as a reference gene to control for 
equal cDNA amount used in reactions. 
 
4.12 WESTERN BLOT 
Tissues were homogenised with Precellys bead homogeniser, and total protein 
extracted with 1% Triton-X in 50 mM Tris, 150 mM NaCl buffer, pH 7.6. 
Proteins were separated with SDS-PAGE, blotted on PVDF membrane and 
visualised using the following primary antibodies incubated overnight at 4°C: 
CTH (Proteintech,12217-1-AP), SDHA (Abcam, ab14715), ACTB (Santa Cruz, 
sc1616), alpha Tubulin (Santa Cruz Cat #sc-5286) and MTHFD2 (Abcam, 
#37840). 
4.13 DNASE I HYPERSENSITIVE SITE ANALYSIS 
Distal regulatory DHSs were identified using public data deposition from 
DNase I -seq experiments (Thurman et al., 2012). A DHS was considered a 
likely regulatory site of the target gene if it located <500 kb from the coding 
region, and its sensitivity to DNase I treatment correlated >0.85 with the 
sensitivity of a DHS in the target promoter across analysed samples. 
4.14 STATISTICAL ANALYSES 
All statistical testing was performed by using Student’s t-test or ANOVA where 
indicated. 
Outliers were removed from the metabolomics data using ROUT method 
(Q = 1%) (GraphPad Prism 6.0). False discovery rate was controlled using 
Benjamini-Hochberg method with the critical value of 0.2. 
PCA plots were created in Metaboanalyst 2.0 with autoscaled data. Missing 
values were estimated using KNN method. 
4.15 CELL CULTURE EXPERIMENTS 
Human myoblasts were treated with actinonin for 16 hours before analysis. 
ATF4 silencing was performed with SilencerSelect© oligos (Sigma) according 




5 RESULTS AND DISCUSSION 
5.1 MITOCHONDRIAL REPLICATION DEFECTS MODIFY 
CELLULAR DNTP POOLS, ONE-CARBON 
METABOLISM AND GLUCOSE CONSUMPTION (I) 
5.1.1 MITOCHONDRIAL MYOPATHY INCREASES GLUCOSE UPTAKE 
FOR DE NOVO SERINE SYNTHESIS 
In study I, we aimed to characterise the metabolic consequences of mtDNA 
replication defects by using a mouse model for mitochondrial myopathy 
(MM), the Deletor mouse. These mice carry a dominant TWNK defect, and 
they faithfully replicate the human disease by accumulating mtDNA deletions 
and COX-deficient muscle fibers (Tyynismaa et al., 2005). We also found 
mtDNA deletions in the heart and consequent COX-deficient and SDH-
positive cardiomyocytes (Figure 7). 
 
Figure 7 Left, multiple mtDNA deletions in Deletor heart (PCR amplification). Right, enzyme 
activity staining (COX, brown; SDH, blue) from the heart of WT and Deletor mice. 
COX-deficient and SDH-positive cardiomyocyte found from Deletor heart (black 
arrow). Scale bars 50 µm. 
Metabolic profiling of the muscle and heart of the Deletor mice was performed 
by measuring the concentration of 107 metabolites by UPLC/MS. This 
revealed a genotype-specific metabolic fingerprint due to mitochondrial 
dysfunction (Figure 8). Individual quantifications showed that increased 
steady-state serine level was the most significant change in both tissues 
(Figure 8). Interestingly, we have previously found that Deletor muscle 
upregulates the expression of phosphoglycerate dehydrogenase (PHGDH) and 
phosphoserine aminotransferase 1 (PSAT1), which are enzymes that catalyse 
the first two steps in de novo serine synthesis (Figure 8) (Tyynismaa et al., 
2010). These enzymes are part of the transcriptional response which increases 
the expression of genes with an amino acid response element in their 
promoters (Tyynismaa et al., 2010). The induced expression of serine 
biosynthesis enzymes and increased serine steady-state level suggested 
activated serine biosynthesis in Deletor muscle and heart.  
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Figure 8 Left, principal component analysis of metabolomics data from skeletal muscle of 
WT and Deletor mice. Plot shows genotype-specific separation of the groups. 
Middle, quantification of serine levels in skeletal muscle and heart. Right, serine 
biosynthesis pathway. 
Serine is synthesised de novo from glucose, and we found a highly increased 
in vivo 2-[18F]-fluoro-2-deoxy-D-glucose ([18F]-FDG) uptake in the muscle 
and heart of the Deletor mice (Figure 9). To test if glucose is directed into 
serine biosynthesis, we administered [U-13C]-glucose to Deletor and WT mice 
via tail vein injections and followed the incorporation of glucose-derived 
carbons into serine after a 15-minute chase (Figure 10). This time point is in 
the linear range of serine synthesis (Figure 10). The fully [13C]-labelled serine 
(m+3) was significantly increased in Deletor heart compared to WT mice 
showing induction of de novo serine synthesis (Figure 10). 
Figure 9 In vivo [18F]-FDG uptake in skeletal muscle (star), heart (white arrowhead) and 
kidney (white arrow). Right, quantifications of the uptake in tissues. 
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PHGDH is a metabolic gate-keeper which can divert glucose consumption 
from glycolysis into serine synthesis. For example, cancer cells induce the 
expression of PHGDH to synthesise serine for cellular growth (Possemato et 
al., 2011). Flux experiments in cultured cells with labelled glucose have 
indicated that glucose carbons are incorporated into serine and lactate in equal 
rates implying that serine is a major glucose-consuming pathway (Locasale et 
al., 2011). Therefore, our results suggest that the increased glucose uptake in 
mitochondrial diseases supports serine synthesis and might not be a 
compensatory response to generate ATP through glycolysis. 
Figure 10 Left, 13C-labelled glucose carbons are incorporated into the three-carbon backbone 
of serine. Middle, quantification of m+3 serine in the heart of WT and Deletor mice 
after administration of [U-13C]-glucose, chase for 15 minutes. Right, labelling of m+3 
serine in heart in the function of time. 
5.1.2 SERINE SYNTHESIS SUPPORTS INCREASED 
TRANSSULFURATION 
Since serine can serve as a substrate in multiple cellular reactions, we next 
sought an explanation for the increased serine synthesis in Deletor mice. We 
searched for genes that share evolutionary history with PHGDH and are, 
therefore, likely to be linked to de novo serine synthesis. Functionally related 
gene groups are typically preserved together in evolution, and this has recently 
been shown to be a powerful trait when predicting functionally interdependent 
pathways (Li et al., 2014). The top five hits for PHGDH include cystathionine 
beta synthase (CBS) and cystathionine gamma lyase (CTH), which are the first 
two enzymes in the transsulfuration pathway (Figures 11, 12). Interestingly, 
CBS uses serine and homocysteine as substrates to produce cystathionine, the 
level of which was increased in the heart of Deletor mice. We next measured 
the expression levels of CBS and CTH and found highly induced expression of 
CTH in muscle and heart, but the level of CBS was not detectable by western 
blot in WT or Deletor mice (Figure 11). 
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Figure 11 Left, genes co-evolving together with PHGDH (CLIME analysis). Scores in brackets 
indicate CLIME-scores. Red lines show species that have lost PHGDH. Figure 
modified from CLIME. Right, expression of CTH in the heart and skeletal muscle of 
WT and Deletor mice (western blot). 
Transsulfuration pathway produces cysteine, which is an amino acid used in 
protein synthesis and metabolic pathways. Cysteine is the rate-limiting 
metabolite in glutathione synthesis, which is a major cysteine-dependent 
pathway (Lu, 2013). Elevated expression of GCLC, a catalytic subunit of the 
first step in glutathione synthesis, together with the higher concentration of 
gamma-glutamylcysteine in the Deletor heart indicated increased glutathione 
synthesis (Figure 12).  
 
Figure 12 Schematic picture of methyl cycle, serine biosynthesis, transsulfuration and 
glutathione synthesis. Picture summarises the findings from Deletor heart: 
increased metabolites shown in red. 
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Glutathione is a key metabolite in nucleotide metabolism as it forms the core 
in the hydrogen donor system, which provides hydrogen molecules for 
ribonucleotide reductases in dNTP synthesis (Sengupta and Holmgren, 2014). 
The role of glutathione in mitochondrial dysfunction has been widely studied, 
but the essential role of glutathione in dNTP synthesis has commonly been 
overlooked because of its important role in ROS scavenging, which is often 
associated with mitochondrial dysfunction (Atkuri et al., 2009). Intriguingly, 
induced de novo serine synthesis for glutathione production has recently been 
shown to be essential in cancer cells due to the high need of dNTPs in cell 
proliferation (DeNicola et al., 2015). In quiescent cells dNTPs are used for 
mtDNA maintenance, and therefore, we hypothesised that mtDNA replication 
stress might induce dNTP synthesis in post-mitotic tissues and result in the 
detected increased serine-driven glutathione production (Bourdon et al., 
2007). We measured the levels of dNTPs from Deletor muscle lysates and 
detected increased levels of all four pools dATP, dTTP, dGTP and dCTP. 
Increased and imbalanced dNTP pools are directly mutagenic and 
compromise the integrity of both mitochondrial and nuclear genomes (Garcia-
Diaz et al., 2014). Therefore, the metabolic response increasing dNTP pools is 
a likely contributor to the mtDNA mutagenesis in the Deletor mouse. 
Figure 13 The levels of dNTP pools in skeletal muscle of WT and Deletor mice. Abbreviations: 
FC, fold change. 
5.1.3 MITOCHONDRIAL DISEASE REMODELS ONE-CARBON 
METABOLISM 
Nucleosides are the precursors for dNTPs, and they are produced de novo from 
amino acids and ribose-5-phosphate via purine and pyrimidine synthesis 
pathways. De novo purine synthesis and the conversion of dUMP to dTMP 
require carbon units to be incorporated to their nitrogenous bases. These 
carbons are provided by the folate cycle, which is a metabolic pathway that 
uses amino acids as input and donates 1C-units to nucleoside synthesis and to 
other key metabolic processes reviewed above (Tibbetts and Appling, 2010). 
Interestingly, Deletor muscle and heart showed increased protein expression 
of MTHFD2 and MTHFD1L, which are the enzymes of the mitochondrial folate 
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cycle, which produces formate for de novo purine synthesis (Figure 14). 
Mthfd2 was earlier found to be a part of the transcriptional response in 
Deletors together with serine biosynthesis enzymes (Tyynismaa et al., 2010). 
These changes, together with induced dNTP levels, predicted changes in the 
folate cycle, which prompted us to characterise the folate metabolism in the 
Deletor mouse. 
Figure 14 Schematic picture of serine synthesis and 1C-metabolism. Picture summarises the 
findings from Deletor skeletal muscle. Red indicates increased level of 
expression/concentration. Formate in green indicates reduced concentration. 
Metabolites or enzymes with black font were not changed or not measured. 
The activation of the mitochondrial folate cycle was coupled with active [18F]-
folate uptake by the Deletor muscle increasing THF, 5-methyl-THF and 
methylene-THF levels (Figure 14). When the mice were supplemented with 
folinic acid (5-formyl-THF), Deletor muscle showed a drastic increase in 5/10-
formyl-THF pool, whereas only a modest increase in the WT animals was 
detected (Deletors 6-fold increase, WT 2-fold increase). These data suggest 
that mitochondrial myopathy modifies the demand of folate in the affected 
tissue. However, folinic acid supplementation did not ameliorate disease 
pathogenesis (the number of COX-deficient muscle fibres, mtDNA deletion 
load) nor affect the expression of the transcription response genes Mthfd2, 
Fgf21, Psat1 or Phgdh. These data indicated that the pathological changes of 
MM are not improved by increased nutritional folate availability. 
An important 1C-carrier for purine synthesis is the cytoplasmic 10-formyl-
THF, which is dependent on formate production by mitochondria. Formate is 
produced in the mitochondria from methylene-THF by a series of reactions 
catalysed by MTHFD2/2L and MTHFD1L (Figure 14). Deletor muscle 
contained reduced formate concentration (p<0.0001) indicating either an 
induced utilisation or defective synthesis. The synthesis requires the 
conversion of methylene-THF to 10-formyl-THF by MTHFD2, which is 
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dependent on NAD+ cofactor. A study in HEK293 cells with mtDNA depletion, 
induced by a dominant negative POLG mutation, reported increased 
expression of MTHFD2 and activation of analogous stress response to Deletor 
muscle (Bao et al., 2016). The authors concluded that in their model MTHFD2 
catalyses a reverse reaction producing methylene-THF leading to impaired 
mitochondrial formate production due to low NAD+ level (Bao et al., 2016). In 
Deletors, the reoxidation of NADH is impaired leading to low NAD+ level, 
which might also underlie defective formate production (Khan et al., 2014). 
However, reports from the cancer field have shown that mitochondrial folate 
pathway is activated due to the induction of the formate-dependent purine 
synthesis (Ben-Sahra et al., 2016). These observations indicate a context-
dependent function of MTHFD2 and mitochondrial folate cycle. The role of 
MTHFD2 in the muscle of Deletor mice remain unclear until further in vivo 
flux and knock-down experiments. 
An alternative reason for the induced mitochondrial folate cycle in Deletor 
muscle might be nicotinamide adenine phosphate (NADPH) production since 
NADPH can be produced from mitochondrial and cytoplasmic 10-formyl-THF 
(Fan et al., 2014). Increased glutathione synthesis, together with possible 
NADPH production, in Deletors point toward a hypothesis that folate cycle can 
act as a NADPH-producing stress pathway to ensure efficient reduction of 
oxidised glutathione. 
5.1.4 MOUSE MODEL FOR IOSCA REPLICATES THE HUMAN 
DISEASE 
We created another mouse model with a TWNK defect to see if the identified 
metabolic stress pathways have relevance for other mtDNA maintenance 
disorders. This mouse carries a recessive IOSCA mutation (c. 1526 A>G, 
p.Y509C), which causes severe neurodegeneration in humans.  The mutation 
was introduced into exon 3 of Twnk by homologous recombination. Correct 
recombination of the targeting construct into the mouse genome was verified 
by southern blotting. 
The mice were born in Mendelian proportions and weighed significantly 
less starting from 9 months of age. A subset of male mice (5/21) had epileptic 
seizures induced by handling. Histopathological examination revealed 
arborisation of the apical dendritic trees of the hippocampus. However, no 
COX deficient muscle fibres were detected, and the quality of mtDNA was 
intact in the muscle and brain, but a modest reduction of mtDNA copy number 
was detected in liver (fold change -1.3, p <0.05). 
5.1.5 IOSCA MUTATION DOES NOT INCREASE SERINE SYNTHESIS 
BUT LEADS TO THE LOSS OF DNTP POOLS IN MUSCLE 
As Deletor mice showed metabolic reprogramming in the muscle, we 
examined these pathways in IOSCA mice. General reduction in amino acid 
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levels was detected, but no signs of induced serine synthesis, transsulfuration 
or remodelling of 1C-metabolism were found from the muscle. However, dNTP 
pools were drastically reduced in IOSCA muscle, which was an opposite 
finding compared to the Deletor mouse where dNTPs were increased (Figure 
15). 
The reduced dNTP pools were not sufficient to induce mtDNA depletion in 
muscle of IOSCA mice, which is consistent with other mtDNA depletion 
models with dNTP synthesis defects (Tyynismaa and Suomalainen, 2009). 
Our findings show that the IOSCA mutation modifies cellular dNTP pools, 
which suggests that mtDNA depletion in human IOSCA patients might be due 
to limited dNTP availability. This fits together with the fact that most gene 
defects causing mtDNA depletion compromise cellular dNTP synthesis 
(Suomalainen and Isohanni, 2010). 
The IOSCA mouse is a valuable new model when studying the disease 
mechanisms in the future. Also, nucleoside treatment has been lately proposed 
as a treatment for dNTP pool disorders, and the IOSCA mouse is a great tool 
to test this intervention as a treatment for IOSCA or for mitochondrial 
encephalohepatopathies. 
Figure 15 The level of dNTP pools in skeletal muscle of WT and IOSCA mice. Abbreviations: 
FC, fold change. 
5.1.6 BLOOD CYSTATHIONINE IS INCREASED IN MITOCHONDRIAL 
DISEASE PATIENTS 
To clarify if the metabolic changes in our mouse models have relevance in 
human patients, we performed metabolomics analysis from patient blood and 
muscle samples. MM patient muscle had increased concentration of serine, 
cystathionine and glutamate indicating that the similar response pathway as 
in Deletor mice is also activated in MM patients. We also found that 
cystathionine was increased in the blood of various mitochondrial disease 
syndromes (PEO, IOSCA, MELAS and MIRAS) when compared to the control 
subjects (PEO and IOSCA reported in (Nikkanen et al., 2016), MELAS and 
MIRAS is unpublished data). This indicates that metabolite biomarkers could 
potentially be used in the diagnosis of mitochondrial diseases together with 
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other novel biomarkers, such as FGF21 and GDF15 (Lehtonen et al., 2016; 
Suomalainen et al., 2011). 
5.2 MTORC1 INDUCES METABOLIC REMODELING IN 
MITOCHONDRIAL MYOPATHY (II) 
In study I, we found increased levels of amino acids and induction of 
transsulfuration and 1C-metabolism in the Deletor mouse indicating that 
mtDNA replication dysfunction leads to an activation of cytoplasmic anabolic 
pathways. This guided us to study nutrient sensing pathways in detail, and we 
sought an explanation for the increased anabolism in the Deletor mouse. 
5.2.1 MTORC1 ACTIVITY IS INDUCED IN MITOCHONDRIAL 
MYOPATHY 
Mechanistic (mammalian) target of rapamycin complex I (mTORC1) is 
responsive to cellular nutritional state and is a major regulator of cellular 
metabolism (Saxton and Sabatini, 2017). In fed state, mTORC1 is 
phosphorylated, which activates cellular anabolism and blocks catabolic 
pathways, e.g. autophagy. This promotes growth by inducing protein, 
nucleotide and lipid synthesis (Laplante and Sabatini, 2012). The overlap of 
the mTORC1-regulated pathways and our findings in Deletor muscle, 
prompted us to study mTORC1 metabolism in MM. 
Phosphorylation of ribosomal protein S6 is an indication for mTORC1 
activity since it is phosphorylated by S6 kinase that is a direct mTORC1 target 
(Ma and Blenis, 2009). When activated, mTORC1 induces cellular growth and 
activates protein synthesis by directly regulating the activity of cytoplasmic 
ribosomes (Ma and Blenis, 2009). The phosphorylation status of S6 in Deletor 
muscle, which was analysed by immunohistochemistry, showed a mosaic 
induction in single muscle fibers (Figure 16). Interestingly, the muscle fibers 
with the most severe respiratory chain deficiency (COX-, SDH+) showed 
intense pS6 staining. These data indicated that primary mitochondrial 
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dysfunction activates mTORC1 in skeletal muscle and prompted us to study its 
role in the metabolic stress response and disease pathogenesis. 
Figure 16 Enzyme activity staining (COX, brown; SDH, blue) and immunohistochemistry with 
anti-pS6 antibody from consecutive skeletal muscle sections. pS6-positive muscle 
fibers in Deletor are often COX- or COX-/SDH+ (circled fibers).  
5.2.2 INHIBITION OF MTORC1 DECREASES SERINE BIOSYNTHESIS, 
TRANSSFULFURATION AND ONE-CARBON METABOLISM 
We inhibited mTORC1 activity in 22-month-old Deletor mice by rapamycin 
treatment for 70 days (dose 8 mg/kg/d, intraperitoneal injections) to evaluate 
its role in MM. The treatment reduced the phosphorylation of S6 protein 
showing efficient inhibition of mTORC1. 
The inhibition of mTORC1 completely abolished MTHFD2 protein 
expression and also reduced the Mthfd2 messenger RNA (mRNA) level 
(Deletor rapa vs Deletor veh: p<0.01) (Figure 17). This was coupled with the 
reduction of folate intermediate levels to WT-levels after rapamycin 
treatment, which indicates that mTORC1 activation is underlying the 
remodelling of 1C-metabolism in Deletor mice (Figure 17). Rapamycin-
treatment also rescued the induction of transsulfuration enzyme CTH and 
reduced the mRNA expression of de novo serine biosynthesis enzymes Phgdh, 
Psat1, and Psph (Figure 17) (Deletor rapa vs Deletor veh for all serine 
biosynthesis enzymes: p<0.01). The downregulation of all stress response 
pathways indicated that mTORC1 acts upstream of the responses. This 
provided an opportunity to find the regulators of the transcription circuit and 
to test the role of the response pathways on disease pathogenesis. 
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Figure 17 Upper panel, protein expression of MTHFD2 and CTH in mouse groups treated with 
rapamycin or vehicle (western blot). Lower panel, quantifications of folate 
intermediates in skeletal muscle of mouse groups in the treatment trial. 
5.2.3 ATF4 INDUCES THE METABOLIC STRESS RESPONSE IN 
MITOCHONDRIAL MYOPATHY 
The regulators that activate the transcription response in MM are unknown. 
In cancer, mTORC1 activation is known to regulate gene expression by 
stabilising ATF4 transcription factor, which binds to the target promoters (e.g. 
MTHFD2) and induces their transcription (Ben-Sahra et al., 2016). We 
studied the role of ATF4 in a myoblast culture system and induced 
mitochondrial dysfunction by actinonin treatment, which leads to 
upregulation of MTHFD2 expression (Richter et al., 2015) (Figure 18). We 
found robust induction of ATF4 expression after the treatment. Knocking 
down the expression of ATF4 completely blocked the induction of MTHFD2 
expression, which strongly indicates that ATF4 is an upstream regulator of the 
transcriptional response in cultured cells. This supports the conclusion that 
ATF4 mediates mTORC1-regulation in MM muscle (Figure 18). 
Figure 18 The mRNA expression of ATF4 and MTHFD2 in myoblasts after actinonin-treatment 
(RT-qPCR). Silencing of ATF4 expression was done with siRNA (siATF4). 
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Figure 19 (A) The levels of dNTP pools in skeletal muscle of mouse groups treated with 
rapamycin or vehicle. (B) MtDNA deletions in Deletor skeletal muscle after 
rapamycin or vehicle treatment and quantification of signal, semi quantitative PCR 
amplification. Non-deleted fragment was amplified to control for equal DNA amount. 
(C) Quantitative analysis of deletion load in MT-ND1 and MT-ND4 of mouse groups 
treated with vehicle or rapamycin, triplex QPCR. 
5.2.4 RAPAMYCIN AMELIORATES RESPIRATORY CHAIN 
DYSFUNCTION 
As mTORC1 also regulates nucleotide metabolism, we hypothesised that 
mTORC1 contributes to the dNTP pool maintenance and mtDNA mutagenesis 
in Deletors. The increased dNTP pools were completely rescued after 
rapamycin-treatment, which was coupled with significant reduction in mtDNA 
deletions (Figure 19). The reduction of mtDNA deletion load further predicted 
a beneficial effect of mTORC1 inhibition on disease manifestation. Indeed, the 
number of both COX- and COX-/SDH+ muscle fibres were reduced (Figure 
20). This was consistent with reduced circulating serum FGF21, which is a 
mitochondrial myopathy disease marker (Figure 20). However, no 
mitochondrial biogenesis or changes in the expression of respiratory chain 
complexes were detected, which indicates that the treatment mechanism was 
independent from mitochondrial biogenesis. All other previous treatment 
strategies for MM, e.g. NAD+ precursors, PARP-inhibitors and ketogenic diet, 
have induced mitochondrial biogenesis (Ahola-Erkkila et al., 2010; Khan et al., 
2014; Pirinen et al., 2014). Our data suggest that chronic induction of cellular 
anabolism by mTORC1 might be a key contributor in MM progression. 
Therefore, rapamycin treatment should be considered when designing 






Figure 20 Left, enzyme activity staining (COX, brown; SDH, blue) of Deletor mice treated with 
rapamycin or vehicle. Middle, the number of COX- and SDH+ muscle fibres of 
Deletors. Right, circulating FGF21 level (ELISA). 
MTORC1 activation has also been reported in neuronal cultures with primary 
mtDNA mutation in ATP6, which causes Leigh disease (Zheng et al., 2016). 
The authors concluded that mTORC1 inhibition had a beneficial effect in 
cultured neurons since rapamycin increased the ATP content of the cells. 
Interestingly, mTORC1 activation was also detected in neurons treated with 
rotenone or oligomycin, which are inhibitors of respiratory chain complexes I 
and V, respectively (Zheng et al., 2016). In addition, rapamycin extends the 
lifespan of NDUFS4 knock-out mice (Johnson et al., 2013). These studies 
indicate that the metabolic stress response we describe in MM might have a 
role beyond mtDNA maintenance diseases, and our study provides a possible 
mechanistic explanation for the beneficial effect of rapamycin in 
mitochondrial dysfunction. 
5.3 A COMPLEX NON-CODING LOCUS REGULATES 
DNA POLYMERASE GAMMA IN THE CENTRAL 
NERVOUS SYSTEM (III) 
To search for putative regulatory elements from the genomic loci of mtDNA 
maintenance genes, we used 1) experimental genome-wide data from the 
ENCODE database to find elements that drive wide-spread expression and 2) 
de novo prediction tools to search for regulators that drive highly specific 
spatio-temporal expression and are not captured with the limited sample set 
used in ENCODE. 
5.3.1 A NON-CODING RNA, LINC00925, ASSOCIATES WITH POLG 
EXPRESSION 
Promoters, regulatory regions and actively transcribing genes are open 
chromatin structures and, therefore, sensitive to DNase I treatment. They are 
thus called DNase I hypersensitive sites (DHS) (Gross and Garrard, 1988; 
Thurman et al., 2012). Thurman et al. found that the DNase I sensitivity of 
distal regulatory sites and their target promoters correlate across cell types 
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since both structures need to be open at the same time in order to have a 
functional link (Thurman et al., 2012). They performed genome-wide DNase I 
sensitivity analysis of 125 primary cell and cancer cell lines, correlated DNase 
I sensitivity of distal DHSs with all promoters in the genome and, thereby, 
identified putative regulatory sites genome-wide (Thurman et al., 2012). We 
utilised this DHS data to analyse the genomic regions of the mtDNA 
maintenance genes TWNK, POLG, POLG2, SSBP1 and TFAM for potential 
regulatory sites. DHSs were considered putative regulatory sites if they 
localised within 500 kb from the coding region of the analysed gene and their 
DNase I sensitivity correlated >0.85 with a DHS in the target promoter. 
The DHS analysis revealed 123 putative regulatory sites for POLG, which 
stood out from other analysed genes (TWNK (0), SSBP1 (1) and TFAM (5) 
POLG2 (0)) (Figure 21). The high number of putative regulatory sites for POLG 
indicated that its transcription is under a complex regulatory circuit. 
Surprisingly, no DHSs were identified for the POLG accessory subunit, 
POLG2, even though POLG and POLG2 are both required for the functional 
heterotrimer (Yakubovskaya et al., 2006). This indicates that POLG2 
expression is not rate-limiting for POLG function.  
Figure 21 (A) The number of DHSs identified for mtDNA maintenance genes and for the 
genes in the POLG locus (B) Distribution of POLG DHSs (red) in the genomic locus. 
(C) Schematic picture of genes surrounding LINC00925. 
The majority of the POLG DHSs locates in a cluster that overlaps a lncRNA, 
LINC00925, 33 kb upstream from POLG coding region (Figure 21). This 
implies a regulatory role of LINC00925 in POLG transcription. We detected 
LINC00925 expression only in different brain regions and in the SH5Y 
neuroblastoma line, but no expression was found in muscle or in non-neuronal 
HepG2 and U2OS cell lines. The mRNA expressions of Ai854517, the mouse 
homolog of human LINC00925, and Polg significantly correlate during 
developmental stages of mouse cerebellum (E18.5 and post-natal day 0, 3, 6, 
9; 3 mice per time point) (Figure 22). In addition, in situ hybridisation of Polg 
and Ai854517 showed overlapping staining patterns in mouse brain (Figure 
 
57 
22). These results indicate that LINC00925 is regulating POLG expression in 
the CNS but LINC00925 knock-down experiment is required to further 
confirm the functional connection. 
Figure 22 Left, Expression of Polg and Ai854517 in mouse cerebellar development (3 
samples per time point: E18, post-natal days 0, 3, 6 and 9). Right, In situ 
hybridisation of Polg and Ai854517 in adult mouse brain. Abbreviations: CTSS, cap 
analysis of gene expression hits in the transcription start site; HC, hippocampus; M, 
molecular cell layer; PC, Purkinje cell layer; GC, granule cell layer 
5.3.2 POLG PROXIMAL PROMOTER DRIVES TISSUE-SPECIFIC 
EXPRESSION IN VIVO 
We next tested if the Polg proximal promoter has intrinsic tissue-specific 
properties in vivo and used it to drive expression of a marker gene, lacZ, in 
transgenic mouse embryos. The expression of lacZ can be detected by an 
enzymatic staining resulting in precipitation of blue colour in cells. The 
staining penetrates through the whole embryo at developmental stage E12.5 
and we, therefore, used this time point in our studies. To our surprise, Polg 
proximal promoter did not drive ubiquitous transcription, rather lacZ 
expression was detected in specific regions of the nervous system: dorsal root 
ganglia, developing motoneurons of the neural tube and midbrain. These data 
indicate that Polg proximal promoter is a nervous system specific promoter at 
E12.5.  
Figure 23 Left, lacZ expression driven by Polg promoter in E12.5 mouse embryo. Expression 
in developing midbrain (black arrows) and dorsal root ganglia (grey arrows). Red 
lines indicate sectioning planes. Scale bars 100 µm. 
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5.3.3 THREE ENHANCER ELEMENTS ARE PREDICTED TO DRIVE 
POLG EXPRESSION 
The CNS-specific properties of the Polg proximal promoter guided us to search 
for enhancer elements (EEs) that might drive POLG expression in other 
tissues. We used Enhancer Element Locator (EEL), which is a de novo 
prediction tool that searches for putative EEs in genomic regions (Hallikas et 
al., 2006). EEs have clusters of transcription factor binding sites (TFBSs) 
which form secondary protein-protein interactions with each other. Secondary 
interactions are critical for the function of EEs since they create a ‘protein raft’ 
on the DNA sequence, which mediates the regulatory function of the enhancer. 
To find EEs from a DNA sequence, EEL searches for regions that have 1) 
conserved TFBSs and 2) conserved distances between the TFBSs which 
maintain the secondary interactions (Palin et al., 2006). The analysis provides 
a score for each predicted EE, which reflects the likelihood of the predicted 
region to be a functional enhancer. Regions scoring higher than 500 have been 
shown by others to be good candidates for enhancer regions (Hallikas et al., 
2006). 
The analysis of the genomic loci of POLG and other mtDNA maintenance 
genes revealed four EEs that scored higher than 500 (Figure 24). These EEs 
located closer than 100 kb from the analysed genes and were found with 
human, rat and mouse comparisons. Three of these EEs were predicted to 
regulate POLG. The fourth EE was located 100 kb upstream of TWNK, and 
several genes reside between the putative enhancer and TWNK coding region, 
which indicates that this EE is not a TWNK-specific regulator (Figure 24). It 
was, therefore, not selected for further analysis. The three POLG EEs were all 
nearly 90% conserved in human, rat and mouse comparisons and the EEL 
scores for EE1, EE2 and EE3 were 768, 671, 522, respectively. Intriguingly, 
these enhancers were located in the introns of LINC00925, which we earlier 
linked to POLG expression by DHS analysis. Non-coding RNAs are known to 
function together with EEs, which synergistically induce the transcription of 
the target promoter (Mattick, 2010). 
Figure 24 Predictions for enhancer elements in the genomic loci of mtDNA maintenance 
genes. EEL-scores indicated by red bars. Protein coding genes are indicated by 
black lines (picture not in scale). 
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5.3.4 THREE ENHANCER ELEMENTS DRIVE POLG EXPRESSION TO 
SPECIFIC NEURONAL SUBPOPULATIONS IN SPINAL CORD 
AND BRAIN 
We generated reporter mouse lines to validate the enhancer predictions in 
vivo. The vector constructs contained each of the EEs, HSV-TK minimal 
promoter and lacZ as a reporter gene. We chose HSV-TK minimal promoter 
since it only drives expression in a context of a functional enhancer. All tested 
enhancers are functional elements in vivo and drive expression in distinct 
regions of the developing nervous system in E12.5 embryos. 
The mouse line carrying EE1 showed intense staining in the neural tube, 
but the most rostral and caudal neural tube regions lacked dorsal expression 
(Figure 25). EE2 and EE3 showed overlapping expression profiles in the 
neural tube, and they drive intense expression in the dorsal part, but the 
expression gradually fades toward the ventral neural tube. In addition, EE2 is 
active in the dorsal root ganglia (DRG) (Figure 25). 
Figure 25 (A)-(C) Expression driven by enhancer elements 1, 2 and 3 in E12.5 mouse 
embryos. Sectioning planes indicated by red lines. Black line in (A) shows region 
with dorsal expression in the developing neural tube whereas rostral and caudal 
regions lack the dorsal expression (black arrows). (D)-(F) Neural tube expression in 
(D) EE1: proliferating immature neurons (grey arrow), (E) EE2: dorsal neural tube 
(grey arrow) and dorsal root ganglia (black arrow) and (F) EE3: dorsal neural tube 
(grey arrow). (G)-(H) Midbrain expression driven by (G) EE1, (H) EE2 and (I) EE3. 
Scale bars 100 µm. 
All three EEs also drive expression in distinct regions of the developing brain. 
EE1 drives highly specific expression in the midbrain, which co-localises with 
Islet1/2-positive motoneuron progenitors of the oculomotor complex (Figure 
26). These oculomotor neurons innervate the extraocular muscle (EOMs) and 
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the muscle of the upper eye lid. EE2 is active in the superficial stratum of the 
superior colliculi, and EE3 drives expression in the dorsolateral midbrain, 
including both the ventricular and mantle zones (Figure 25). 
 
Figure 26 Immunofluorescent co-staining with antibodies against β-Gal and Islet1/2 (marks 
motoneuron progenitor cells) in EE1 midbrain. The lacZ staining of the area is 
indicated by black arrow in Figure 25G. Scale bars 20 µm. 
5.3.5 ENHANCERS DRIVE POLG EXPRESSION IN ADULT BRAIN AND 
SPINAL CORD 
Since enhancers have different temporal characteristics, we tested the function 
of the three POLG EEs in adult mice. EE1 does not drive expression in adult 
animals, which suggests that its function is restricted to development. 
However, EE2 and EE3 showed overlapping staining patterns in the adult 
spinal cord, and they drive expression in the sensory interneurons of the dorsal 
horns and cells surrounding the central canal (Figure 27). We found that these 
neurons are often calbindin-positive, which indicates that the enhancers drive 
expression in glutamatergic interneurons (Figure 28) (Todd, 2010). In 
addition, EE2 is also active in the adult brain driving strong expression in 
hippocampus, olfactory bulb and cerebellum (Figure 27). The expression 
pattern of EE3 in adult brain was inconsistent and, therefore, not conclusive. 
Figure 27 LacZ expression in adult mouse brain and spinal cord. Dashed line in the EE2 
spinal cord indicates the dorsal horn shown in top panel of EE3 (black arrows). 
Expression is also detected in cells around the central canal (black arrowheads). 
Scale bars 100 µm if not stated otherwise. 
POLG is the only known mtDNA polymerase and thought to be essential for 
all cells that have mitochondria. However, our detailed characterisation of the 
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expression regulation of POLG identified regulators that drive the expression 
only in the nervous system. Other regulators that drive POLG expression in 
other cell types likely exist, but they were not captured by methods used in this 
thesis. The regulatory locus we identified is, therefore, likely to be part of a 
complex regulatory circuit that drives the spatio-temporal expression of 
POLG. This is supported by our DHS analysis, which found 123 different 
regulatory sites for POLG, some of which did not overlap with the LINC00925 
coding region. These DHSs are likely POLG-regulators driving the expression 
in other tissues, but the experimental validation of all of them is beyond the 
scope of this thesis. 
 
Figure 28 Immunofluorescent co-staining of lacZ-expressing neurons in the dorsal horns of 
the spinal cord. Staining with anti-calbinin (red) and anti-β-Gal (green) antibodies. 
Scale bars 20 µm. 
5.3.6 MIR-9 IS EXPRESSED FROM THE LINC00925-ENHANCER 
LOCUS 
In addition to three EEs, we also found a second regulatory RNA, MIR-9, 
located within the intron of LINC00925. MicroRNAs encoded in the introns 
of other genes are commonly transcribed together with the primary transcript 
(Kim and Kim, 2007). Accordingly, MIR-9 and LINC00925 expressions 
significantly correlate (r=0.68, p = 0.005) in mouse cerebellar development, 
which supports the notion that these two transcripts are co-expressed. 
Furthermore, the co-expression suggested that the MIR-9 targets are 
downregulated when LINC00925 is expressed to drive POLG transcription. To 
identify the targets of MIR-9, we used microRNA target prediction programs, 
which suggested 6 common targets for MIR-9 (LDLRAP1, MTHFD2, FSTL1, 
CAPZA1, PRDM1, PRRX). Methylene-tetrahydrofolate dehydrogenase 2, 
MTHFD2, was especially interesting since it is part of the stress response for 
mitochondrial replication defects and a previously validated target of MIR-9 
(Bao et al., 2016; Nikkanen et al., 2016; Selcuklu et al., 2012). 
We suggest that POLG and MTHFD2 are inversely co-regulated in specific 
neuronal populations, which might have important implications in mtDNA 
maintenance diseases. The neurons in which the enhancer-lncRNA locus is 
active also expresses MIR-9, which might block the induction of mitochondrial 
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stress response during mitochondrial replication disease, which makes these 
neurons especially vulnerable to POLG defects. 
5.3.7 NEURONAL DEATH IN THE ENHANCER REGIONS OF A POLG 
PATIENT 
We obtained brain and spinal cord autopsy samples from a patient with POLG-
disease and found neuronal death in the enhancer-active regions. The 
oculomotor nucleus showed spongiotic degeneration, and neurofilament 
staining of the spinal cord revealed severe loss of neurons in the dorsal 
columns (Figure 29). This indicates that the enhancer-active regions are 
especially sensitive to POLG defects, and the death of these neurons might 
underlie the clinical symptoms of POLG patients: sensory neuropathy and 
PEO.  
Figure 29 Left, C8-level spinal cord section of a POLG patient (neurofilament staining in 
brown). Dorsal columns show pallor (star) but motoneurons of the ventral horns are 
preserved (black arrow). Scale bar 1mm. Right, oculomotor nucleus of POLG 
patient shows spongiotic degeneration (haematoxylin-eosin staining). Scale bar 50 
µm.  
5.3.8 IS THE CAUSE OF PEO CENTRAL OR EXTERNAL? 
EE1 drives POLG expression specifically in the oculomotor complex, which 
indicates that these neurons have a high requirement for mtDNA replication 
or repair – possibly due to the high firing rate and the need of mitochondrial 
respiratory chain function. The oculomotor nucleus innervates the extraocular 
muscles (EOMs) and the muscle of the upper eyelid, levator palpebrae 
superioris. The dysfunction of these muscles causes PEO, but whether the 
primary cause is the degeneration of the muscles (external) or the nerve 
(central), is clinically challenging to determine since the functions of the 
muscle and the innervating nerve are interdependent. In addition, EOMs 
accumulate high levels of COX-negative fibres (3.34% in subjects older than 
60 years) and mtDNA deletions also during normal aging, which can be 
misinterpreted as a primary EOM defect in PEO patients (Yu-Wai-Man et al., 
2010). 
The general MM symptoms highly vary depending on the affected gene. 
POLG MM patients often have severe nervous system involvement with mild 
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muscle phenotype. The specific expression of POLG in the oculomotor 
complex and the nervous system involvement of POLG PEO patients suggest 
that the cause of PEO in POLG cases might be of central origin.  In contrast, 
TWNK patients show clear generalised muscle disease with minor nervous 
system involvement, and therefore, the cause of PEO in TWNK patients is 
most likely external. Also, some TWNK patients were found to have 
accumulation of abnormal mitochondria in EOMs that were severely atrophic, 
strongly supporting the EOMs to be the cause of PEO (Suomalainen et al., 
1992). We, therefore, suggest that PEO can be a primary external or central 
defect, depending on the affected gene 
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6 CONCLUSIONS AND FUTURE 
PROSPECTIVES 
This thesis characterised in detail two novel aspects of tissue-specificity in 
mitochondrial metabolism and dysfunction. First, we identified novel 
metabolic stress responses activated by mtDNA replication stress and 
discovered that mTORC1 is the master regulator of these responses. Second, 
to the best of our knowledge, we are the first to identify tissue-specific 
regulatory elements of a nuclear-encoded mitochondrial protein, and we 
describe here a non-coding regulatory locus for POLG. 
Mitochondrial dysfunction only manifests in specific tissues. Due to the 
mechanistic advances in the research of mitochondrial metabolism, we know 
that no simple explanation exists for the tissue-specificity of mitochondrial 
diseases. The reason why a mitochondrial protein defect only affects a specific 
tissue, can lie in various signalling or metabolic pathways essential for that cell 
type. The cell type that is the most dependent on the function of the affected 
pathway is likely to encounter cellular dysfunction or death, which manifests 
as mitochondrial disease. The disturbance can be caused by primary or 
secondary consequences and can be modified by downstream stress 
responses. These stress responses are possibly, in part, underlying the 
manifestations of disorders caused by a variety of gene defects. One example 
of such disorders is PEO, which can be caused by mutations in an array of 
mitochondrial proteins that do not have obvious functional connection. The 
gene defects can, however, have similar secondary consequences and stress 
responses in the affected tissues. Different mutations in the same 
mitochondrial protein can also lead to completely different tissue 
manifestations, which indicates that the downstream consequences of defects 
within one protein can trigger different metabolic or signalling disturbances. 
Prime examples of such proteins are TWNK and POLG, which were the 
proteins of interest in this thesis. Our work characterised in detail the 
metabolic stress responses for mitochondrial diseases revealing novel 
contributors for the tissue-specific manifestations of mitochondrial diseases. 
The detailed characterisation of the biochemical consequences of 
mitochondrial diseases is valuable when designing specific treatment options. 
The lack of in vivo data from mitochondrial disease models has hindered the 
development of effective treatments for these diseases. To gain more insight 
into the disease mechanisms of mitochondrial disorders, we utilised the 
existing model for MM, the Deletor mouse, and created a novel disease model 
for IOSCA, which is the first mouse model for mitochondrial 
encephalohepatopathy. These models are valuable tools for testing metabolic 
interventions as treatment for mitochondrial diseases.  
Our results from the mouse studies identified the metabolic 
rearrangements caused by mitochondrial replication defects. We found that 
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mitochondrial myopathy induces a transcription response that is orchestrated 
by the activation of mTORC1 and is mediated by the ATF4 transcription factor. 
This leads to 1) remodelling of 1C-metabolism 2) disturbed whole-cellular 
dNTP pools and 3) diverted glucose consumption into serine biosynthesis and 
transsulfuration. We show that inhibition of the whole stress response by 
rapamycin is beneficial for the disease pathogenesis, which indicates that the 
stress response accelerates disease progression. However, targeting the 
different branches of the stress response is critical when evaluating the 
beneficial or detrimental effects of the individual pathways. Some of the 
activated pathways are likely to be beneficial for the disease, and therefore, 
specific targeting of the responses that accelerate the disease progression 
might lead to better treatment strategies. 
We also suggest a second new mechanism that might underlie the 
sensitivity of specific cell populations to mtDNA replication defects. We 
identified a genomic regulatory locus which drives POLG expression in the 
CNS and functions through three enhancer elements and LINC00925. The 
locus expresses MIR-9 in the same neurons in which it drives POLG 
expression. Interestingly, these neurons seem to be especially sensitive to 
POLG defects causing neuronal death in POLG patients in regions where the 
non-coding locus is active. This raises an intriguing hypothesis that the non-
coding locus might sensitise these neurons to mtDNA replication stress. MIR-
9 is an attractive candidate to facilitate this effect since it functions in trans 
and targets the mitochondrial folate enzyme MTHFD2. MIR-9, therefore, 
blocks the induction of the mitochondrial stress response, which can be critical 
in neurons with mtDNA replication stress. However, these hypotheses need to 
be tested in appropriate disease models in the future.  
In recent years, many new diseases genes have been found due to the 
development of next-generation sequencing techniques. Despite the rapid 
identification of new disease genes, many patients suffering from 
mitochondrial diseases are still without a genetic diagnosis. A part of these 
patients is likely to have pathogenic mutations in the non-coding regulatory 
regions which are not captured by exome sequencing. Whole-genome 
sequencing enables finding these variants but results in a high number of 
possible pathogenic changes because 1) non-coding regions allow more 
variation in the DNA sequence than coding-regions, 2) non-coding regions do 
not have a codon code and 3) prediction tools cannot be used to evaluate the 
pathogenicity of the variant. Also, the verification of non-coding pathogenic 
variants often requires in vivo experiments due to the lack of cell culture 
models. Therefore, identifying regulatory regions for mitochondrial disease 
genes is critical in finding new pathogenic non-coding variants. In this thesis, 
we identified a regulatory region for the most frequent cause of mitochondrial 
diseases, POLG, which offers the first candidate region for regulatory 
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